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Abstract
CD9, a member of the tetraspanin family, is highly expressed on platelets (50,000-80,000 copies per
platelet). Tetraspanins have been implicated in modulation of integrin function, and it is hypothesized that
CD9 will modulate GPIIb-IIIa, the major platelet integrin.
The association between CD9 and GPIIb-IIIa was analyzed using immunoprecipitations and confocal
microscopy. These two proteins were found to associate with each other, particularly at areas of plateletplatelet contact and at the periphery. Confocal analysis revealed CD9 localization was most intense at
platelet-platelet contact, as well as in platelet filopodia and lamellipodia, but there is a lack of CD9 at
areas of platelet-matrix contact. Co-localization with F-actin decreased as platelets progressed through
the stages of spreading.
In order to analyze CD9 contributions to platelet function, a Fab fragment was generated from mAb7, an
antibody which binds with high affinity to the large extracellular loop of CD9. Fab fragments were used to
avoid complications of bound antibody crosslinking CD9 with the platelet FcγRII receptor. Confocal
analysis of platelet spreading indicated that CD9 perturbation by mFab7 resulted in increased platelet
spreading on a variety of matrices, although platelet adhesion was unaffected on all matrices except
fibrin. Platelet-platelet interactions, including aggregation and disaggregation, were studied using light
transmission aggregometry. CD9 perturbation increased the extent of platelet aggregation in response to
threshold levels of agonist, with diminished effect with more potent agonists such as TRAP (Thrombin
Receptor Agonist Peptide). CD9 perturbation also diminished, but did not completely inhibit, platelet
disaggregation induced by eptifibatide. Interestingly, CD9 perturbation did not alter platelet-mediated clot
retraction of platelets in PRP (Platelet rich plasma). In response to CD9 alteration by mFab7, both
increased fibrinogen binding and platelet activation (as evidenced by CD63 and P-selectin expression)
were elicited in the presence of threshold ADP levels. Both responses were dependent on presence of
low-level agonist, as CD9 perturbation in the absence of agonist yielded no effect.
Cytoskeletal isolation revealed that CD9 perturbation results in increased incorporation of actin and other
cytoskeletal molecules into the platelet core cytoskeleton. Immunoprecipitations results showed
increased CD63 incorporation into the tetraspanin web, although the level of CD9 coprecipitation with
GPIIb-IIIa was unaffected. A preliminary analysis of tyrosine phosphorylation, particularly Akt, did not
reveal alterations on tyrosine phosphorylation of signaling molecules.
These results suggest that CD9 functions as a scaffold, organizing molecules into specific domains on
the platelet surface. It appears to function as a “gatekeeper” for GPIIb-IIIa activation, particularly
modulating activation and aggregate stability at low levels of agonist.
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ABSTRACT
CD9, a member of the tetraspanin family, is highly expressed on platelets
(50,000-80,000 copies per platelet). Tetraspanins have been implicated in
modulation of integrin function, and it is hypothesized that CD9 will modulate
GPIIb-IIIa, the major platelet integrin.
The association between CD9 and GPIIb-IIIa was analyzed using
immunoprecipitations and confocal microscopy. These two proteins were found
to associate with each other, particularly at areas of platelet-platelet contact and
at the periphery. Confocal analysis revealed CD9 localization was most intense
at platelet-platelet contact, as well as in platelet filopodia and lamellipodia, but
there is a lack of CD9 at areas of platelet-matrix contact. Co-localization with Factin decreased as platelets progressed through the stages of spreading.
In order to analyze CD9 contributions to platelet function, a Fab fragment
was generated from mAb7, an antibody which binds with high affinity to the large
extracellular loop of CD9. Fab fragments were used to avoid complications of
bound antibody crosslinking CD9 with the platelet FcγRII receptor. Confocal
analysis of platelet spreading indicated that CD9 perturbation by mFab7 resulted
in increased platelet spreading on a variety of matrices, although platelet
adhesion was unaffected on all matrices except fibrin. Platelet-platelet
interactions, including aggregation and disaggregation, were studied using light
transmission aggregometry. CD9 perturbation increased the extent of platelet
aggregation in response to threshold levels of agonist, with diminished effect with
more potent agonists such as TRAP (Thrombin Receptor Agonist Peptide). CD9
perturbation also diminished, but did not completely inhibit, platelet
disaggregation induced by eptifibatide. Interestingly, CD9 perturbation did not
alter platelet-mediated clot retraction of platelets in PRP (Platelet rich plasma). In
response to CD9 alteration by mFab7, both increased fibrinogen binding and
platelet activation (as evidenced by CD63 and P-selectin expression) were
elicited in the presence of threshold ADP levels. Both responses were dependent
on presence of low-level agonist, as CD9 perturbation in the absence of agonist
yielded no effect.
Cytoskeletal isolation revealed that CD9 perturbation results in increased
incorporation of actin and other cytoskeletal molecules into the platelet core
cytoskeleton. Immunoprecipitations results showed increased CD63
incorporation into the tetraspanin web, although the level of CD9 coprecipitation
with GPIIb-IIIa was unaffected. A preliminary analysis of tyrosine
phosphorylation, particularly Akt, did not reveal alterations on tyrosine
phosphorylation of signaling molecules.
These results suggest that CD9 functions as a scaffold, organizing
molecules into specific domains on the platelet surface. It appears to function as
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a ―gatekeeper‖ for GPIIb-IIIa activation, particularly modulating activation and
aggregate stability at low levels of agonist.
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CHAPTER 1 INTRODUCTION
1.1 Overview
Platelets are anucleate, disc-shaped cell fragments generated from
megakaryocytes. They circulate through the vasculature and play a dual role in
that they are critical for regulating hemostasis and wound healing (constituting a
primary defense against bleeding) and thrombosis (which can lead to thrombotic
disorders under pathological conditions). Platelets express a wide array of
adhesion receptors that mediate adhesion, spreading, and cell-cell interactions.
Tetraspanins are one family of proteins that modulate cell adhesion events in
concert with integrins. Platelets express several tetraspanins—most prominently
CD9—at 50,000-80,000 copies per platelet.
Tetraspanins constitute a unique class of integral membrane-spanning
proteins. Four transmembrane domains, intracellular carboxy and amino termini,
two extracellular loops, and unique motifs in the large extracellular loop
characterize this family of proteins. Tetraspanins have been implicated in
regulation of platelet integrin function, such as platelet adhesion, activation, and
aggregation, yet the exact role of CD9 in human platelets has remained unclear.
Based upon data in other cell model systems, it is hypothesized that CD9 may
regulate platelet adhesive functions by regulating integrin activation and postreceptor occupancy events, such as thrombus stability.
1.2 Purpose of the Study
The purpose of this study is to determine the role of CD9 in human
platelets. For the first time, the functional activity of CD9 in platelets will be
defined by using a well-characterized anti-CD9 Fab fragment generated from an
antibody (mAb7) that has been shown in other studies to modulate cell adhesive
events. These data are critical for understanding which aspects of platelet
function tetraspanins most influence and how tetraspanins, specifically CD9, may
regulate platelet response to vascular injury. It is also hypothesized that CD9
function likely occurs on the platelet surface—such as adhesive functions or
interaction with the integrin GPIIb-IIIa—mediated through its extracellular loops.
This is because specific motifs in its cytoplasmic domains known to interact with
platelet signaling molecules or adaptor proteins have not been identified. Thus,
CD9 through its extracellular loop regions may function at threshold levels of
activation, with a role in regulating the extent of integrin activation.
Through understanding the function of CD9, the influences of platelet
pathophysiological responses can be further appreciated. These findings may
lead to advances in wound healing, hemostasis and thrombosis, and vascular
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bed diseases such as acute coronary syndromes by targeting CD9 and its
function for pharmacological intervention.
1.3 Aims and Research Questions
1.3.1 Specific Aim 1
Determine the localization and protein partners of CD9 in human platelets.
Flow cytometry will be performed to analyze CD9 expression in resting and
activated platelets, which will shed insight if CD9 is primarily important in platelet
activation or activated platelets, or if it primarily regulates other proteins during
platelet events. Flow cytometry will also reveal relative surface expression of
other members of the tetraspanin web in resting and activated platelets.
Immunoprecipitation and confocal microscopy will be used to determine
the association and localization of CD9 and GPIIb-IIIa, the primary platelet
integrin. It is anticipated that CD9 might exert its effect through regulating the
extent of GPIIb-IIIa activation. These results will yield insight into the effect of
platelet activation and integrin ligand binding on the CD9-GPIIb-IIIa association
by platelets spread on substrate and in suspension. Experiments with platelets
expressing a mutant GPIIb-IIIa will provide preliminary insight into possible areas
of GPIIb-IIIa critical to its association with CD9.
Confocal microscopy will also be used to analyze the localization of CD9
into platelet spreading structures such as filopodia, lamellipodia, and plateletplatelet contact sites to initially determine if CD9 is involved in platelet adhesive
events. Co-localization with F-actin will yield insight into CD9’s linkage with the
cytoskeleton, although this could occur directly or indirectly through other
members of the tetraspanin web.
1.3.2 Specific Aim 2
Determine platelet functions affected by CD9 perturbation. The effect of
CD9 on platelet events will be determined by creating a Fab fragment which
binds to the extracellular region of CD9. The full-length antibody has been shown
to have a functional effect in smooth muscle cells and Chinese hamster ovary
cells. A Fab fragment is used here to ensure that results are due to CD9 ligation
without involvement of the receptor FcγRII.
Major platelet functions involved in this study include platelet aggregation
and disaggregation, platelet adhesion and spreading on four substrate
matrices—all of which are ligands for GPIIb-IIIa, ligand binding and platelet
activation (via flow cytometry), and platelet-mediated clot retraction. These
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events are mediated by GPIIb-IIIa, and it is anticipated that CD9, by regulating
this integrin, will alter these events.
Aggregation and disaggregation, ligand binding, and platelet activation will
be analyzed using low concentrations of platelet agonists. It is anticipated that
CD9 will function as a gatekeeper for integrin activation, and that its impact will
be most pronounced at threshold levels of platelet activation. Stronger levels of
agonist would be expected to overwhelmingly activate the integrin, regardless of
CD9 signaling.
1.3.3 Specific Aim 3
Determine mechanisms involved in the contribution of CD9 to platelet
function. This includes examination of the tetraspanin web, incorporation of
cytoskeletal proteins into the core cytoskeleton, phosphorylation of key signaling
molecules, and the effect of CD9 perturbation on each.
CD9 may function as a membrane protein scaffold, and may be critical in
recruiting cell surface molecules and organizing signaling complexes in the
tetraspanin web. In this role, CD9 may function to keep proteins in contact with or
away from GPIIb-IIIa or to maintain a desirable (active or inactive) conformation
of GPIIb-IIIa. Flow cytometry will analyze the impact of CD9 perturbation on
association of CD9, GPIIb-IIIa, and CD63 in resting and activated platelets.
Platelet core cytoskeletons will be isolated and analyzed to determine the role of
CD9 on the incorporation of cytoskeletal proteins. Platelet signaling molecules
will also be evaluated, primarily phosphorylation of Akt. Research in our lab has
shown the Akt pathway to be the primary CD9 signaling pathway (Kotha 2008).
However, total tyrosine phosphorylation will also be analyzed to examine a
possible involvement of another pathway.
It is anticipated that the linkage of CD9 to the cytoskeleton or signaling
molecules is indirect, through GPIIb-IIIa, due to the short intracellular regions of
CD9, although a novel CD9 binding partner may be discovered. Since CD9 is
likely involved in mediating activation of GPIIb-IIIa, its cytosolic partners could
also be altered.
1.4 Significance
Genetic research shows a biological significance for tetraspanins in
mammalian systems. Inactivation of the tetraspanin TALLA-1 causes X-linked
mental retardation (Zemni 2000); CD9 and CD81 knock-out mice have reduced
fertility, with double knock-out mice being completely infertile (Kaji 2000, LaNaour
2000, Miyado 2000, Rubinstein 2006); and CD37 knock-out mice have reduced
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immune response. In the platelet system, CD151 or TSSC-6 knock-out mice
have impaired integrin outside-in signaling (Goschnick 2006, Lau 2004).
Currently available studies of CD9 functions in platelets have yielded
limited information. At present, there have been no published studies showing
defects or abnormalities in platelet function in the CD9 knock-out mice; however,
there is no information regarding expression levels of (and possible
compensation by) other tetraspanins or integrins. Use of anti-CD9 antibodies
have consistently activated signaling mechanisms through the receptor FcγRII,
making interpretation of results difficult. In this study, Fab fragments will be used
in place of antibodies; thus, CD9 ligation can still be achieved without the
involvement of the FcγRII.
The results of this project will lead to better understanding of the basic
biology of CD9 and its role in platelet function. This will add to the knowledge of
platelet function that could lead to the development of pharmacological agents
that target CD9 and arrest thrombosis.
These results will also lead to a broader understanding of cell adhesive
function and better define a family of molecules that regulate integrins, key
receptors in cell adhesion, differentiation, and proliferation of cells. The functional
role of the CD9-GPIIb-IIIa interaction is, at present, poorly defined. The ability of
tetraspanins to modulate integrin conformation, as well as membrane complexes,
ligand binding, and integrin-associated cell signaling pathways, will be more
clearly defined, and our understanding of communication through platelet-platelet
and platelet-matrix interactions will be advanced.
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CHAPTER 2 REVIEW OF LITERATURE
2.1 Platelets
2.1.1 Platelet Formation and Function
Platelets are small cell fragments released from megakaryocytes,
composed of a membrane, cytoplasm, granules, and organelles. Approximately
1011 platelets are produced in the human body on a daily basis; once released
from the bone marrow megakaryocytes, they circulate in the blood for seven to
ten days (Harker 1969). Their function is to maintain vascular integrity by
regulating hemostasis and thrombosis.
Megakaryocytes are derived from hematopoietic stem cells (HSCs), which
evolve from the multipotent haemangioblast, the precursor for all blood and blood
vessel cells. The HSC yields the early Common Myeloid Progenitor (CMP), which
is cloned as the (Granulocyte, Erythrocyte, Megakaryocyte and Monocyte)
Colony-Forming Unit (CFU-GEMM). The CMP differentiates into the
Megakaryocyte-Erythroid Progenitor (MEP), which yields both the erythroid and
megakaryocytic lineages, controlled by GATA-1 (which regulates granulocyte
and monocyte precursors). Cytokines and chemokines, in response to
environmental factors, allow differentiation of MEP into the highly proliferative
BFU-MK (Megakaryocyte Burst-Forming Unit) or the more mature CFU-MK
(megakaryocyte colony-forming unit). These cells progress into megakaryoblasts,
which are incapable of cell division but able to replicate DNA (Deutsch 2006).
This yields the immature, polyploid (up to 128 N) megakaryocyte (Tomer 1988),
containing elevated RNA levels, prominent ribosomes and rough endoplasmic
reticulum, alpha and dense granules, and a primitive demarcation membrane.
The maturing megakaryocyte develops a horseshoe-shaped nucleus and an
expanded cytoplasm and amplifies platelet organelles and the demarcation
membrane, which is continuous with the plasma membrane (Breton-Gorius
1976). The cell surface expresses GPIIb-IIIa (IIb3), GPIX, and GPIb, and the
granules contain von Willebrand factor (vWF), platelet factor 4, βthromboglobulin, fibrinogen, coagulation factor VIII, and factor V (Breton-Gorius
1976). Megakaryocytes occur in about one in 2000 nucleated bone marrow cells,
although this number may increase ten-fold in response to thrombocytopenia
(Branehog 1975).
The megakaryocyte can extend long proplatelet projections; the
demarcation membrane serves primarily as a membrane reservoir for proplatelet
formation. These are filled with the proper specific organelles and granule
contents, which migrate from the cell body to the proplatelet ends, to give rise to
new circulating platelets (Italiano 1999, Italiano 2003). A single megakaryocyte
may give rise to 2000-5000 new platelets (Long 1988). Two models suggest how
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platelets arise: platelets may arise and bud off the tip of proplatelet (Choi 1995,
Patel 2005), or there may be preformed territories with internal membranes that
are released by fragmenting from the membrane ( Mori 1993, Zucker-Franklin
1984).
Resting platelets circulate as small discs, approximately 0.5 x 3.0 μm in
humans. An internal microtubule beneath the plasma membrane, composed of
13 stacks of tubulin subunits arranged head-to-tail in protofilaments, maintains
the disc shape (Lecine 2000). It remains unclear whether the microtubule coil has
any other function, as well as any advantage of a disc-shape (Hartwig 2006).
An internal actin filament cytoskeleton maintains platelet integrity. The two
main components of the actin filament cytoskeleton are the membrane skeleton
and the cytoplasmic actin scaffold.
Upon platelet activation, the microtubule reorganizes into multiple short
microtubules that run from the platelet center toward outward protrusions, as well
as a forming a compressed coil in the center of a spread platelet. Microtubule
kinetics is controlled by dynein, a minus-end-directed motor, and kinesins, which
are mainly plus-end-directed motors (Hartwig 2006).
2.1.2 Platelet Physiology
2.1.2.1 Activation by Agonists. Platelets express a number of agonist
receptors: GPVI (collagen) (Clemetson 2001), PAR-1 and PAR-4 (thrombin)
(Coughlin 2005), P2Y1 and P2Y12 (ADP) (Gachet 2006), and receptors for
thromboxane A2 (Thomas 1998) and epinephrine (Pozgajova 2006). A summary
of platelet agonists can be found in Table 2.1.
Platelet agonists can be found in increased concentrations at sites of
vascular injury. They lead to platelet activation, causing shape change, integrin
activation via inside-out signaling, and granule secretion (see Table 2.2).
2.1.2.2 Adhesion and Spreading. Immediately upon vascular injury,
platelets tether to the exposed subendothelium and become activated by the
agonists present at the site of injury (collagen and thrombin). Once activated,
platelets become firmly adherent and will release their storage granules, which
contain ADP and other substances (see Table 2.2). This in turn promotes
additional platelet recruitment and platelet aggregation (Denis 2007) (see Fig 2.1
and Fig 2.2).
Initial platelet tethering is mainly carried out by the GPIb-IX-IV complex
binding to exposed von Willebrand factor (vWF) (see Fig 2.2), which undergoes a
conformational change when bound to the matrix or exposed to high shear
conditions (Bergmeier 2000, Berndt 2001, Ruggeri 2003). The interaction
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Table 2.1

Comparison of Platelet Agonists

Agonist

Receptor

G
Protein

Signaling
Molecules

Effect

Importance

ADP

P2Y1

Gq

PLC
RhoA, Rac,
Src kinase,
PKC

Weak,
transient
activation
of GPIIbIIIa

Shape change,
initiation of
aggregation

P2Y12

Gi2

Inhibit
adenylyl
cyclase
and
cytosolic
cAMP;
activate
PI3K,
Akt/PKB,
Rap1b, src
family
kinases

GPIIb-IIIa
activation,
dense
granule
release

Sustained
aggregation
response,
leading to
thrombus
growth and
stabilization

PAR1

Gq,
G12/13,
Gi

PLC, IP3,
DAG, PKC,
Rho/Rho
kinase,
inhibition of
adenylyl
cyclase

Strong
activation
of GPIIbIIIa in
response
to low
thrombin
levels

Cytoskeletal
rearrangement, shape
change,
degranulation,
adhesion

PAR4

Gq,
G12/13

PLC, IP3,
DAG, PKC,
Rho/Rho
kinase,

Strong
activation
of
GPIIb-IIIa
in
response
to high
thrombin
levels

Cytoskeletal
rearrangement,
shape change,
degranulation,
adhesion



----

Syk, SLP76, PLC

Activation
of GPIIbIIIa

Outside-in
platelet
activation

GPVI,
GPIV

----

Src, Fyn,
Lyn, Syk,
PI3K

Activation
of GPIIbIIIa

Calcium
release

Thrombin

Collagen

(continued)
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Medical
Targets

Ticlopidine
Clopidigrel

Table 2.1 (continued)
Agonist

Receptor

Epinephrine

2adrenergic
receptors

G
Protein
----

Signaling
Molecules

Effect

Importance

Medical
Targets

IP3, DAG,
PKC, PLC

Activation
of GPIIbIIIa

Granule
secretion,
aggregation

Aspirin,
NSAIDS,
others

Source:
Bennett JS. Structure and function of the platelet integrin aIIbb3. J Clin Invest.
2005; 115: 3363-3369.
Gachet C. Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol
Toxicol. 2006; 26: 277-300.
Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide
receptor signaling in platelets. J Thromb Haemost. 2006; 4 (11): 23172326.
Offermans S. Activation of platelet function through G protein-coupled receptors.
Circ Research. 2006; 99: 1293-1304.
Samaha FF, Kahn ML. Novel platelet and vascular roles for immunoreceptor
signaling. Arterioscler Thromb Vasc Biol. 2006; 26: 2588-2593.
Voss B, McLaughlin JN, Holinstat M, Zent R, Hamm HE. PAR1, but not PAR4,
activates human platelets through a Gi/o/phosphoinosite-3 kinase
signaling axis. Molec Pharmacol. 2007; 71 (5): 1399-1406.
Watson SP, Auger JM, McCarty OJT, Pearce AC. GPVI and integrin αIIbβ3
signaling in platelets. J Thromb Haemost. 2005; 3 (8): 1752-1762.
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Table 2.2

Platelet Granules

Granule

Alpha Granules

Dense Granules

Lysosomes

# per platelet

80

7

2-4

Contents

Growth factors,
coagulation proteins,
adhesion molecules,
cytokines, cellactivating agents,
angiogenic factors,
platelet-specific
molecules
(coagulation factor V,
thrombospondin, Pselectin, von
Willebrand factor),
endocytosed
molecules (FG);
some contain
exosomes

High concentrations
of small molecules
important to cell
activation (ADP,
serotonin, calcium,
magnesium,
pyrophosphate,
nucleotides)

Components of
endosomallysosomal
degradative
pathway (acid
hydrolases,
cathepsins D and
E)

Development

Fusion of vesicles
budding from transGolgi apparatus in
megakaryocytes, or
fusion of vesicles
endocytosed from
the plasma
membrane

Endogenous
synthesis in
megakaryocytes;
may develop from
fusion with endocytic
vesicles

Different
ontogeny than
alpha or dense
granules, yet
share common
antecedents

Disorders

Gray platelet
syndrome (variable
bleeding diathesis;
small abnormal
vesicles; defect in
formation or packing
of alpha granule)

Dense Storage Pool
Deficiency
(decreased thrombus
formation, varying
hemostatic defect)

9

Figure 2.1 Platelet Spreading Structures
Platelets adhering to a matrix initially have a round morphology, but immediately
extend fingerlike projections termed filopodia. Then lamellipodia are extended,
which have been compared to webbing between a duck’s toes. Finally, the
membrane fully extends to allow the platelet to cover a large surface area.
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vWF
Collagen
GPIb
α2β1
GPIIb-IIIa
FG

Figure 2.2 Platelet Activation Leading to Adhesion and Spreading or
Aggregation
Interaction of the platelet receptors GPIb and α2β1 with vWF or collagen on the
exposed subendothelium leads to platelet activation and spreading on the
subendothelium. Nearby platelets are recruited to form a thrombus and maintain
hemostasis. Platelets can also be activated by soluble agonists (such as ADP),
leading to platelet activation, granule secretion, and aggregation via binding and
crosslinking GPIIb-IIIa on adjacent platelets.
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between GPIb and vWF can withstand very high shear rates, yet is characterized
by fast association and dissociation rates, allowing slow platelet translocation
along the vessel wall (Savage 1998). In the absence of VWF, GPIb can still
initiate platelet tethering through other ligands, possibly thrombospondin-1
(Bergmeier 2006, Jurk 2003). Under cases of low shear, a direct interaction
between exposed collagen in the subendothelium and the platelet receptors αβ1
and GPVI can support adhesion (Clemetson 2001).
Collagen and thrombin at the site of injury lead to platelet activation and
inside-out signaling. As platelets then become activated, platelet integrins—
particularly GPIIb-IIIa—transition from their inactive conformation to an active
conformation capable of binding agonists and transmitting intracellular signals.
Activated integrins then bind their ligand on the vessel wall, develop filopodia and
lamellipodia and become fully spread, and release the contents of their granules
(see also Table 2.2). ADP and thromboxane A2 are among the granule contents
released, promoting activation, and leading to the formation of a platelet plug and
arrest of bleeding (Coleman 2004).
2.1.2.3 Aggregation. The major platelet protein involved in aggregation
is GPIIb-IIIa (Fig 2.2), which is present in the platelet membrane and alpha
granules, providing an extra pool of the integrin on the platelet surface upon
platelet activation and granule release (Bennett 2005). Absent or dysfunctional
GPIIb-IIIa leads to the bleeding defect Glanzmann thrombasthenia, characterized
by platelets that are unable to form stable aggregates (Nurden 2005). Fibrinogen
is the major GPIIb-IIIa ligand, capable of causing platelet aggregation by crosslinking GPIIb-IIIa on adjacent platelets. Fibrinogen can also be converted to fibrin
by thrombin; the resulting fibrin can cross-link with fibronectin, contributing to
thrombus stability by anchoring the thrombi to the vessel wall.
Thrombus formation is not abolished in fibrinogen-deficient mice, and
other ligands for GPIIb-IIIa include vWF and FN (Ni 2000). vWF plays an
essential role in occlusive thrombi formation at both arterial and venous shear
rates (Nanda 2005, Ni 2000). Absence of vWF prevents additional thrombus
growth and occlusion (Ni 2000). Additionally, in mice with reduced plasma FN
levels, thrombus formation is highly defective, with increased emboli and delayed
vessel occlusion (Ni 2003). However, this defect is specific to arteries, as no
defect is found at venous shear (Matsukova 2006).
2.1.2.4 Cytoskeletal Rearrangement. In order for the platelet to be able
to extend filopodia and lamellipodia, release its granules, and form stable
aggregates, it must be able to rearrange its cytoskeleton.
Upon agonist exposure, platelets lose their discoid shape, becoming
spherical and then rapidly extending filopodia and spreading on a surface. Shape
change is driven by reorganization of the cytoskeleton and a doubling of the actin
filament content (converted from globular actin) (Hartwig 2006).
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The membrane skeleton is first disassembled. It is released from actin and
becomes centered in spread platelets. This is partly mediated by adducin, which
is dissociated from spectrin and the barbed ends of actin. Adducin is inactivated
by PKC-mediated phosphorylation, phosphatidylinositides, or calciumcalmodulin-binding (Matsuoka 2000).
The cortical actin network is then disrupted. Gelsolin (20,000 per platelet)
and cofilin (100,000 per platelet) function to fragment actin filaments, resulting in
F-actin disassembly: gelsolin severs and caps barbed ends, while cofilin
promotes the disassembly of actin from pointed ends. Increasing cytosolic
concentrations of calcium triggers a conformational change in gelsolin, allowing it
to bind and fragment actin. Gelsolin remains bound to the barbed end of actin
until it is removed by polyphosphoinositides. Cofilin must be dephosphorylated to
become active, requiring 15 to 60 seconds for maximal activation (Falet 2005).
Gelsolin and cofilin, combined with the release of adducin from spectin-actin,
remodel the membrane and actin cytoskeletons.
New actin filament assembly is initiated from the ends of actin filaments
adjacent to the plasma membrane. Formation of lamellipodia, required for
circumferential platelet spreading on the surface, requires a large amount of Factin. This need is met as platelets double their cellular F-actin content as
filaments form and grow through barbed-end growth, via uncapping and
fragmentation of barbed filament ends and activation of actin-related protein 2/3
(Arp 2/3) (Hartwig 2006). Approximately 50% of gelsolin is dissociated from
barbed ends of actin filaments, and the Arp 2/3 complex binds to actin near the
barbed ends and nucleates a second filament. Upstream proteins and
phospholipids, including Wiskott-Aldrich syndrome protein (WASP) family
members and cortactin, regulate Arp 2/3 nucleation activity. Actin filament
assembly is terminated via CapZ constitutively capping exposed barbed
filaments; filopodial growth in cells can be promoted by modulating the activity of
CapZ via proteins such as VASP/Mena (Gertler 1996, Mejillano 2004).
2.1.2.5 Clot Retraction. Platelet-mediated clot retraction is a necessary
step for consolidation of a platelet thrombus. Retraction keeps the thrombus from
falling apart by making it less susceptible to fibrinolysis (Denis 2007) and aids in
wound closure, as the damaged edges are drawn together (Parise 1999).
Interactions between GPIIb-IIIa and fibrin (which is cleaved from
fibrinogen by thrombin) results in outside-in signaling. Clot retraction is brought
about as tyrosine residues on the cytoplasmic tail of GPIIb are phosphorylated
(Phillips 2001, Shattil 2004), and cytoskeletal assembly and molecular
translocations occur (Parise 1999). Clot retraction appears to be regulated
through multiple pathways, including activation of PLCß and Rho kinase, which
activate MLC kinase and inhibit MLC phosphatase, and PLCγ2 downstream of
Src kinase (Suzuki-Inoue 2007). This process is dependent on the contractile
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protein thrombasthenin, as well as the interaction between actin and myosin
(Suzuki-Inoue 2007).
2.1.3 Platelet Receptors
2.1.3.1 G Protein-Coupled Receptors. G-protein coupled receptors are
one family of surface receptors involved in platelet activation (see Fig 2.3). These
receptors contain seven membrane-spanning domains, and an intracellular and
an extracellular terminus, and are also referred to as ―seven transmembrane
receptors‖ or serpentine receptors. The intracellular domain of each of these
receptors is coupled to a distinct heterotrimeric G protein, belonging to either the
Gi, Gq, G12/13, or Gs families. Upon activation, the G protein triggers an
intracellular signaling cascade resulting in platelet shape change, granule
secretion, and platelet aggregation via integrin activation.
G-protein coupled receptors in human platelets include the ADP receptors
P2Y1 and P2Y12, the thrombin receptors PAR-1 and PAR-4, and the
thromboxane A2 receptors TPα and TPβ.
The P2Y1 receptor is coupled to Gq and phospholipase Cβ, which leads to
activation of the small G proteins RhoA and Rac and Src kinases (Kahner 2006).
Activation of PLCβ leads to hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) to inositol triphosphate (IP3) and diacyl glycerol (DAG), leading to calcium
release, PKC activation, and weak, transient activation of GPIIb-IIIa (Gachet
2006, Kahner 2006). P2Y1 is important for platelet shape change, the initial wave
of reversible aggregation, thromboxane A2 generation, procoagulant activity,
adhesion to immobilized fibrinogen, and thrombus formation under shear
(Cattaneo 2005, Murugappan 2006).
P2Y12 is coupled to Gi2 (Gachet 2006). Activation leads to inhibition of
adenylyl cyclase and inhibition of cytosolic cAMP concentration via the Gα
subunit, and activation of phosphoinositide 3-kinase (PI3K), Akt/PKB, Rap1b,
and src family kinases (Gachet 2006, Kahner 2006). This receptor is important
for stable platelet aggregation, in addition to sharing many of the same functions
as P2Y1 (Cattaneo 2005, Murugappan 2006). The combined action of both
receptors is needed for full platelet aggregation in response to ADP (Cataneo
2005). P2Y12-blocking drugs such as clopidigrel and ticlopidine are clinically
being used in the treatment of thrombotic disorders.
PAR1, which responds to low thrombin concentrations, and PAR4, which
responds to higher thrombin concentrations, are activated by cleavage of an
extracellular portion of the receptor. PAR4 is coupled to Gq and G12/13, and
PAR1 is coupled to G1, G12/13, and Gi (Offermans 2006). Gq is coupled to
PLCβ, especially β2 (leading to activation of PKC). G12/13 regulates the
Rho/Rho kinase pathway, and Gi inhibits adenylyl cyclase (Offermans 2006).
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Figure 2.3 Platelet Receptors
A, G protein-coupled receptor; B, Integrin; C, Leucine-rich repeat protein; D,
Immunoglobulin receptor; E, Tetraspanin.
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These steps lead to platelet cytoskeletal rearrangement, resulting in platelet
shape change and platelet degranulation and adhesion (Offermans 2006).
TPα and TPβ are coupled to G13 and Gq, resulting in activation of RhoGEF and PLCβ. Both are important in platelet activation and shape change, and
blockade of these receptors results in increased bleeding times and protection
from thromboembolism (Murugappan 2004).
2.1.3.2 Integrins. Integrins are a family of integral cell-surface receptors
made up of an alpha and a beta chain. Each chain consists of a large
extracellular domain, a single transmembrane domain, and a short cytoplasmic
domain (Fig 2.3). In mammals, 19 alpha and eight beta subunits combine to form
24 integrins (Humphries 2000). They mediate contact between a cell and its
environment and transmit signals across the plasma membrane.
Integrins undergo a highly regulated structural change, providing a
transition from a bent state with a low affinity for ligand binding (inactive) to an
extended, open state with a high affinity for ligand binding (active) (Adair 2002,
Takagi 2002, Vinogradova 2002). Conformational changes resulting from ligand
binding may result in the unmasking of specific epitopes, separate from the
ligand-binding domain, on the integrin. These ―ligand-induced binding sites‖, or
LIBS, offer a means to study integrin activation and ligand binding without
occupying the ligand-binding domain.
Integrin signaling can be grouped into ―inside-out‖ signals, which control
activation of the integrin, and ―outside-in‖ signals, resulting from ligand binding.
Inside-out signaling results from a stimulus from another cell receptor (such as G
Protein-Coupled Receptors), which leads to a stimulus acting on the cytoplasmic
portion of the integrin and modifying the contacts between the cytoplasmic tails,
leading to a change in the transmembrane domains and altering integrin affinity
for ligand and integrin avidity (via integrin clustering on the cell surface). Outsidein signals lead to recruitment of intracellular signaling molecules and cytoskeletal
proteins, resulting in changes in platelet cytoskeleton and morphology (AriasSalgado 2005; Han 2006; Tadokoro 2003).
Platelets express several integrins, including αIIbβ3, which binds
fibrinogen, fibrin, fibronectin, and von Willebrand factor; αvβ3, which binds
vitronectin; α2β1, which binds collagen and laminin; α5β1, which binds
fibronectin; and α6β1, which binds laminin. Of these, αIIbβ3, or GPIIb-IIIa, has
the highest expression level, at 50,000-80,000 per platelet, and has been the
most extensively characterized.
αIIb is composed of 1008 amino acids. The extracellular domain is
composed of an N-terminal β-propeller domain, thigh domain, and two calf
domains. β3 is composed of 762 amino acids, with an extracellular domain
consisting of an A domain, plexin/semaphorin/integrin domain, four EGF
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domains, and a membrane-proximal βTD domain (Xiong 2001). The extracellular
domains of the α and β subunits combine to form an ellipsoid ―head‖ consisting of
the β-propeller and A-domain, and two tails (Ma 2007). The transmembrane
domains of each subunit form alpha helices that are believed to interact when the
integrin is in a resting conformation (Adair 2002, Gottschalk 2005). The
cytoplasmic tails form a complex between the membrane-proximal helices that is
maintained by electrostatic and hydrophobic interactions; disruption of both these
interactions leads to integrin activation (Ma 2006, Vinogradova 2002, Weljie
2002). The membrane-distal regions of the cytoplasmic tails include a divalent
ion-binding site, although the significance of this feature is uncertain (Haas
1996). There is also a phosphotyrosine binding domain critical to integrin
activation (Chen 1994, O’Toole 1995, Van der Geer 1995). More than 20 proteins
have been identified as binding partners, most prominently talin (which links the
integrin to the actin cytoskeleton and is critical in integrin-mediated focal
adhesion formation) (Burridge 1996, Rees 1990). The cytoplasmic domains can
also directly interact with the cytoskeletal proteins myosin, skelemin, filamin, αactinin, and F-actin; the adaptor/signaling proteins paxillin, Shc, and Grb 2; the
protein kinases/phosphatases Src, Csk, Syk, ILK, FAK, and PP1c; and BiP,
Calreticulin, and β3-endonexin (Ma 2007). αIIbβ3 can also bind with the
transmembrane proteins CD36, CD47/IAP, CD98, and CD31, as well as the
tetraspanins CD9, CD63, and CD151, although these interactions likely involve
interactions with the transmembrane and extracellular domains (Ma 2007).
Inside-out signaling of GPIIb-IIIa is initiated by various platelet agonists,
including thrombin, ADP, and collagen; each is capable of initiating inside-out
signaling events, but they likely act cooperatively in a physiological environment.
Agonist signaling leads to activated PKC, which regulates serine/threonine
phosphorylation of GPIIb-IIIa. DAG, calcium, and PI3K regulate GPIIb-IIIa
activation through Rab1b (a small GTPase of the Ras family), thus affecting
binding of proteins, particularly talin, to the cytoplasmic domain of GPIIb-IIIa
(Focosi 2007). The head domain of talin activates GPIIb-IIIa by binding to actin
directly or indirectly through vinculin and α-actinin. The binding of β3-endonexin
can also activate GPIIb-IIIa by binding to the β3 NITY motif. Integrin binding
protein (IBP) binds to αIIb and appears to be involved in integrin activation
(Platelets 2007).
Following inside-out signaling, the integrin GPIIb-IIIa becomes competent
to bind ligands (fibrinogen, fibronectin, fibrin, etc). Ligand binding alters the
conformation of the integrin, as well as inducing integrin clustering. This further
encourages binding of cytoskeletal proteins leading to outside-in signaling. Src
kinases, which are constitutively bound to β3, become activated through
autophosphorylation. This leads to recruitment of Syk and tyrosine
phosphorylation of PLCγ2, which is necessary for lamellipodial formation. SLP-76
and Vav are also involved in regulation of PLCγ2. GPIIb-IIIa can also signal
through Syk-independent cascades (Watson 2005).
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αvβ3 is structurally similar to GPIIb-IIIa, although its alpha chain has a
slightly longer cytoplasmic tail (Suzuki 1986). Vitronectin, not fibrinogen, is the
preferred ligand, although it can bind several RGD-containing ligands (including
osteopontin and adenovirus penton base) (DiGiovine 2001). ADP appears to
induce the high-affinity conformation (Bennett 1997, Helluin 2000).
α2β1 is the only platelet integrin to contain an I domain, which usually
constitutes the primary ligand-binding interface (Emsley 1997). This integrin
binds collagen types I-VI and XI (Kehrel 1995), leading to ADP release (Atkinson
2003, Jung 2000) and phosphorylation of Src kinases, SLP-76, Syk, and PLC
(Inoue 2003). Its absence leads to a bleeding disorder and reduced platelet
response to collagen, although GPVI appears to be most important in collagenmediated platelet activation (Kehrel 1995, Nieuwenhuis 1985).
α5β1 is important for platelet interaction with the fibronectin matrix. Unlike
the β3 integrins, it can support adhesion under static conditions in the absence of
platelet activation (McCarty 2004), although adhesion strength may be increased
upon activation (Garcia 1998). Ligand interaction is unable to promote tyrosine
phosphorylation, calcium release, or shape change (McCarty 2004), limiting the
role of this integrin to initiating the interaction of resting platelets with the
extracellular matrix (Kasirer-Friede 2007).
α6β1 is a receptor for laminins, a component of basement membranes
and the extracellular matrix (Sonnenberg 1988). Platelet activation is not
necessary for ligand binding (Sonnenberg 1991), and binding to laminin does not
appear to induce granule release or aggregation (Nigatu 2006), although it does
induce filopodial formation (Chang 2005).
2.1.3.3 Leucine-Rich Repeat Proteins. GPIb-IX-V is a platelet adhesion
receptor in the Leucine-rich repeat family. Its major function is initiating thrombus
formation at high shear stress in flowing blood (Andrews 2003). It binds to vWF in
the subendothelial matrix or plasma, as well as Mac-1 on neutrophils and Pselectin on activated platelets and endothelial cells (Andrews 2003). Its absence
or dysfunction leads to Bernard-Soulier syndrome, a rare but often severe
bleeding disorder (Andrews 1997, Berndt 2001, Lopez 1998).
GPIb-IX-V consists of GPIbα disulfide-linked to GPIbβ, noncovalently
complexed with GPIX and GPV in a 2:2:2:1 ratio (Fig 2.3) (Andrews 1997, Berndt
2001, Lopez 1998). All components are members of the leucine-rich repeat
family. The N-terminal portion of GPIbα, consisting of eight leucine-rich repeats,
contains binding sites for vWF, Mac-1, P-selectin, α-thrombin, clotting factors
XI/XIIa, and high-molecular-weight kininogen (Berndt 2001).
High shear results in GPIb-IX-V binding von Willebrand factor, which is
rapidly secreted following platelet activation. Following binding, platelets become
activated, leading to shape change, spreading, and granule secretion caused by
cytoskeletal rearrangement, recruiting additional platelets to the developing
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thrombus. GPIb-IX-V signal transduction, involving PI-3-kinase, Syk, Src, and
ERK-1/2, leads to activation of GPIIb-IIIa, mediating platelet aggregation
(Andrews 2003, Berndt 2001).
In order to be competent to adhere and signal, GPIb-IX-V undergoes
multiple post-translational modifications. GPIb sulfation within the ligand-binding
domain regulates adhesion to vWF (Dong 2001, Huizinga 2002, Shen 2000, Tait
2002, Uff 2002) and thrombin (Berndt 2001); glycosylation of GPIb extends the
ligand-binding domain and allows adhesion (Lopez 1998); cytoplasmic
palmitoylation of GPIb and GPIX may regulate surface localization and
association with other membrane proteins (Lopez 1998), and phosphorylation
allows association with the signaling protein 14-3-3 (Bodnar 1999, Gu 1999).
2.1.3.4 Selectins. Selectins are proteins that bind glycoproteins and
glycolipids in a calcium-dependent manner. They consist of an extracellular Nterminal lectin domain adjacent to a domain homologous to epidermal growth
factor, a variable number of short consensus repeats, a single transmembrane
domain, and a C-terminal cytoplasmic domain (Sperandion 2006, Thomas 2006).
Platelets express the P-selectin, also known as CD62P. P-selectin is
found in alpha granules of platelets and is rapidly mobilized to the cell surface
upon platelet activation, where it binds to P-selectin glycoprotein ligand 1 (PSGL1) and Sialyl Lewis X-bearing glycoproteins (Smith 2007). The interaction
between P-selectin and PSGL-1 allows platelet tethering to leukocytes under
shear conditions and may contribute to leukocyte activation (Pitchford 2005,
Zarbock 2006).
2.1.3.5 Immunoglobulin Receptors. Platelet Fc receptors mediate
immune responses to IgG-containing complexes, implicating platelets in the
adaptive immune response. These receptors contain immunoreceptor tyrosinebased activation motifs (ITAMS) (Fig 2.3) (Reth 1989), and upon ligand binding,
Src-family kinases phosphorylate tyrosine residues within the ITAM sequence,
leading to recruitment and activation of Syk or ZAP-70 tyrosine kinase, initiating
downstream signaling events (Fodor 2006). These responses seem to be
regulated by the phosphoinositides PI4,5P2 and PI3,4,5P3 (Booth 2006). The
activation pathways are inhibited by immunoreceptor tyrosine-based inhibitory
motifs (ITIMs), which bind to the downstream tyrosine phosphatases (Jackson
1997). In platelets, ITAM/ITIM signaling may be involved in hemostatic regulation
as well as immune responses (Kasirer-Friede 2007).
Fc receptors are of particular importance in this study due to a localization
and association of Fc receptors with tetraspanins. Anti-CD9 monoclonal
antibodies crosslink CD9 to FcγRII, eliciting a potent activation response. While
the functional relevance of this interaction has yet to be elucidated, tetraspanins
have been shown to negatively regulate FcR signaling independently of coligation, possibly through interactions within the tetraspanin web (Moseley 2005).
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Other receptors coupled to Fc receptors include GPVI, a collagen receptor
(Berlanga 2000, Nieswandt 2000); GPIb-IX-V, a vWF receptor (Wu 2001, Arthur
2005); and potentially C-type lectin receptor-2 (CLEC-2), which has an as-yet
unknown function in platelets (Gross 2006).
2.1.3.6 Tetraspanins. The structure and function of tetraspanins is
discussed more fully in the following sections. Tetraspanin function in platelets is
summarized in Table 2.3.
Platelets express several tetraspanins, among them CD9, CD63, CD151,
and TSSC-6 (Fig 2.3, Fig 2.4, and Fig 2.5). They are believed to modulate
integrin function, and indeed, both antibody-blocking and knockout studies yield
platelets with incomplete GPIIb-IIIa functioning. Megakaryocytes have been
shown to contain the transcripts for the tetraspanins NET5 (TSPAN9) and
TSPAN33, and these may also be expressed at the protein level in platelets
(Senis 2007).
The tetraspanin CD63, with an apparent molecular mass of 30-60 kDa, is
expressed on platelet lysosomes in resting platelets and is expressed on the
platelet surface upon exocytosis triggered by platelet activation. CD63 has been
studied by blocking with a monoclonal antibody. These platelets retained normal
adhesion to fibrinogen, but platelet spreading, F-actin reorganization,
redistribution of vinculin, extensive tyrosine phosphorylation, and phosphorylation
of Focal Adhesion Kinase (FAK) were diminished. CD63 was also shown to be
linked to PI 4-kinase type II (Israels 2005).
The impacts of TSSC-6 and CD151 in platelet function have been studied
using knock-out mice. It is important to note that expression levels of integrin
GPIIb-IIIa is unaffected in these knock-outs (Goschnick 2006, Lau 2004).
TSSC-6 (Tumor-suppressing subchromosomal transferable fragment
cDNA 6) is localized to the cell surface and in intracellular pools in murine
platelets. Mice that are deficient for TSSC-6 exhibit increased tail bleeding time,
increased blood loss, and more rebleeds in a tail-bleeding assay, all features of
unstable hemostasis. They also exhibit secondary instability in a ferric chloride
oxidative injury model, showing greater time to vessel occlusion and a greater
number of emboli forming during the observation period. Impaired ―outside-in‖
signaling of GPIIb-IIIa was evident, as these platelets had delayed clot retraction,
defective spreading, and reduced aggregation at low concentrations of agonist
(≤150 μM PAR-4, 5 μg/ml collagen). However, ―inside-out‖ signaling was
unaffected, as knockout mice showed normal fibrinogen binding, normal binding
of an activation-dependent antibody to GPIIb-IIIa, and normal alpha granule
release (Goschnick 2006).
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Table 2.3

Summary of Tetraspanins in Platelet Function

Tetraspanin

CD9

CD9

CD151

CD63

TSSC-6

Method
Studied

knock-out

antibody
blocking

knock-out

antibody
blocking

knock-out

Species

Mouse

human

mouse

human

mouse

Aggregation

Unknown

unknown

reduced in
response to
PAR4,
collagen,
ADP

Adhesion

Unknown

unknown

unaffected

unaffected

unaffected

Spreading

Unknown

unknown

impaired

Impaired

impaired

Ligand Binding

Unknown

unknown

normal
soluble FG
binding

unknown

normal
soluble FG
binding

Activation

Unknown

unknown

unaffected

unaffected

unaffected/
similar Pselectin
expression

Cytoskeleton

Unknown

unknown

unknown

impaired Factin
reorganization, vinculin
distribution

unknown

Signaling
Molecules

Unknown

unknown

normal
levels of
calcium and
IP3

reduced
phosphorylation of FAK.
IP’s PI4kinase type II.

unknown

Clot Retraction

Unknown

unknown

impaired

unknown

impaired

Other insight

possible
compensation by
another
tetraspanin
or integrins
is unknown

activation
of FcRII
makes
interpretation of
data
difficult

reduced in
response to
PAR4
<150 uM,
Collagen 5
ug/ml.

increased
tail bleeding
time/
rebleeding,
unstable
platelet
thrombi/
more emboli
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Figure 2.4 Schematic of Tetraspanin CD9
TM, Transmembrane domain; EC, extracellular loop. Numbers refer to amino
acid residues. C-C, disulfide bond between cysteine residues. The area circled in
red corresponds to the binding site for mAb7/mFab7.
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CD151
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TSSC6
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IIb
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TSSC6
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Figure 2.5 Tetraspanin Web in Platelets
A, Resting platelet membrane, expressing FcR, CD9, a bent (inactive) GPIIb-IIIa,
CD151, and TSCC6. B, Activated platelet membrane. GPIIb-IIIa now assumes
an extended conformation, capable of ligand binding. CD63 is also brought to the
surface, in association with CD9 and GPIIb-IIIa.
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CD151, also known as PETA-3 (platelet endothelial tetraspan antigen-3),
is physically and functionally associated with GPIIb-IIIa and modulates its
―outside-in‖ signaling. CD151-deficient mice have delayed clot retraction;
reduced aggregation to 500 μM PAR-4, 20 μg/ml collagen, and 10 μM ADP; and
normal adhesion but incomplete spreading on fibrinogen, including reduced
number of filopodia per platelet. Inside-out GPIIb-IIIa signaling was normal, as
these platelets had normal FG binding, normal binding of an activationdependent antibody to GPIIb-IIIa, normal alpha and dense granule secretion, and
normal increases in cytosolic-free calcium and IP3 levels (Lau 2004).
In spite of CD9 expression on the platelet surface being greater than other
tetraspanins, and being greatly studied, it is still poorly understood. It is localized
to the platelet surface membrane and alpha granules (Cramer 1994). Studies
with antibody ligation to CD9 have been inconclusive due to the linkage to the
low-affinity immunoglobulin G receptor, FcγRIIa, in human platelets (Kuruda
1995, Qi 1996), although one study suggests that CD9 regulates platelet function
independently of FcγRIIa (Wu 2000).
CD9 knock-out mice have not shown any critical platelet defects; however,
expression levels of other tetraspanins, integrins, and surface proteins have not
been characterized, allowing the possibility of compensation. Additionally, studies
involving CD9 knock-out platelets have not utilized low concentrations of
agonists, which would be suggested based on studies with TSSC-6 knockout
platelets.
CD9 (see Fig 2.4 and Fig 2.5) is proposed to have roles in platelet
aggregation and spreading. It may facilitate platelet functions via its association
with GPIIb-IIIa or through direct ligand binding, as fibronectin has been shown to
be a ligand for CD9 (Longhurst 2002).
2.2 Tetraspanins
2.2.1 Tetraspanin Structure
Tetraspanins are integral membrane proteins containing four
transmembrane alpha-helices (TM1, TM2, TM3, and TM4), two extracellular
loops (EC1 and EC2), and short intracellular amino and carboxy termini
(Berditchevski 2001, Boucheix 2001, Hemler 2001). EC1, also known as the
small extracellular loop, is flanked by TM1 and TM2, while EC2, also known as
the large extracellular loop, is flanked by TM3 and TM4.
Proteins are identified as tetraspanins based on a shared overall structure
distinct from other proteins with four transmembrane domains and the
conservation of specific amino acid residues in their transmembrane domains
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and the second extracellular loop (Hemler 2001, Maecker 1997). These
characteristic motifs include the conserved cysteine-cysteine-glycine (CCG)
sequence in EC2, which is involved in two of the two to four disulfide bridges
observed in EC2 of all tetraspanins (Seigneuret, 2001). TM1, TM2, and TM3
consist of heptad repeat motifs, containing highly conserved asparagine and
glycine in TM1 and TM2, and conserved leucine and glutamate/glutamine in
TM3. Heptad repeat motifs are noticeably absent in TM4, although it contains
conserved polar amino acids (Kovalenko 2005). There is a highly conserved
asparagine-glycine-glycine motif in EC1 (Kovalenko 2005).
EC2, and rarely EC1, are glycosylated at one or more N-glycosylation
sites, contributing to the overall tetraspanin size that ranges from 20 to 70 kDa
(Yunta 2002).
Crystal structures of full-length tetraspanin proteins have not been
generated, owing to inherent properties of membrane proteins; however, the
crystal structure of the EC2 loop of CD81 has been solved (Kitadokoro 2001).
This showed five alpha-helices arranged in ―stalk‖ and ―head‖ domains, and it is
believed that these structural features are consistent among all tetraspanins
(Kitadokoro 2001).
Tetraspanins are evolutionarily conserved. In addition to mammals, they
have been found in Schistosomes (Wright 1990), early metazoans (Adell 2004),
fungi (Gourgues 2002), and nematodes (Moribe 2004). Currently, more than 30
tetraspanins have been identified.
Tetraspanins are expressed in all human cell types, and most cells
generally express multiple tetraspanins (Levy 2005). Tetraspanins may be
expressed on both the cell surface and on granular membranes (Israels 2005).
Some tetraspanins—such as CD9 and CD81—are expressed in almost all cell
types, while others are more restricted— CD37 in B cells (Schwartz-Albeiz 1988),
RDS/peripherin in retina (Travis 1991), uroplakins in bladder epithelium (Walz
1995), and CD53 in lymphoid-myeloid cells (Maeker 1997).
2.2.2 Tetraspanin Web
Tetraspanins have been implicated in a wide variety of cell processes.
This is likely the result of interactions between tetraspanins and other associated
proteins within tetraspanin webs (which is also known as tetraspanin
microdomains, tetraspanin enriched microdomains, or tetraspanin complexes)
(see also Fig 2.5).
Tetraspanins have the ability to associate with a wide variety of membrane
proteins. Generally, the extracellular domains—mainly EC2—interact with
laterally associated proteins or soluble ligands, the cytosolic regions associate
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with cytoskeletal or signaling molecules, and the transmembrane domains
interact with other proteins necessary for maintenance of the tetraspanin web
(Levy 2005). Thus, the tetraspanin web acts as a molecular facilitator, organizing
membrane proteins and coupling receptors to signaling pathways (Levy 2005).
In differing cell types, the tetraspanin web is composed of different
tetraspanins and partner proteins. It is unclear whether all the tetraspanins in a
certain cell are associated with each other.
Within the tetraspanin web, specific tetraspanins directly associate with a
partner membrane protein (frequently a member of the integrin or
immunoglobulin superfamilies) and other tetraspanin proteins. These
tetraspanins also directly associate with a particular partner protein. Primary
interactions between tetraspanins and partner proteins are believed to be
mediated through extracellular domains, in particular EC2, due to resistance to
Triton-X 100 disruption. The majority of tetraspanin interactions with other
membrane proteins cannot withstand Triton-X 100 treatment, but can withstand
milder detergents and are termed secondary interactions (Serru 1999).
Palmitoylation of intracellular cysteine residues plays an important role in
tetraspanin-tetraspanin interactions; abolishment of this palmitoylation reduces a
tetraspanin’s interaction with other tetraspanins (Charrin 2002, Yang and Claas
2002). Palmitoylation of partner proteins also contributes to their incorporation
into the tetraspanin web (Yang and Kovalenko 2004). Palmitoylation provides a
regulatory mechanism to rearrange the tetraspanin web in response to
stimulation (Dempsey 1996).
The tetraspanin web also includes interactions with cytoskeletal and
signaling molecules. These signaling molecules include Rho GTP-binding
proteins (Schwartz 2000), G protein-coupled receptors and their intracellular
associated heterotrimeric G-proteins (Little 2004), phosphatidylinositol 4-kinase
(Berditchevski 1997, Yauch 1998), and PKC isozymes (Zhang 2001). The
tetraspanin web is linked to the actin cytoskeleton via EWI-2 and EWI-F (SalaValdes 2006).
Tetraspanin-enriched membrane domains are physically and functionally
separate from lipid rafts, although they share some characteristics (Claas 2001,
Hemler 2003). Both can associate with cholesterol and gangliosides and can be
recovered from low-density membrane fractions of sucrose gradients. However,
tetraspanin webs and lipid rafts exhibit differences in membrane solubility and
have different protein content (lipid rafts often contain GPI-linked proteins and
caveolin, which are rarely found in tetraspanin webs) (Berditchevski 2002, Foster
2003, Hemler 2005, Yauch 2000). Lipid rafts may associate with the tetraspanin
web under certain conditions, thereby facilitating signal transduction (Israels
2007).
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With specific regard to the tetraspanin CD9, interactions have been shown
with the integrins α3β1 (Yanez-Mo 1998), α4β1α6β1,α5β1,αIIbβ3 (GPIIb-IIIa),
and precursor β1 (Yunta 2002); the growth factor receptors TGF-α and HB-EGF
(Lagaudriere-Gesbert 1997); immunoglobulin superfamily members FRPP and
EWI-2 (Stipp 2001); CD36 and CD9P-1 (Miao 2001), CD19 (Horvath 1998), and
CD46 (Yunta 2002); the signaling molecules PKC and PI4K (Boucheix 2001);
and the soluble ligands FN (Longhurst 2002), and PSG 17 (Waterhouse 2002).
Many more protein partners will likely be identified in the future.
2.2.3 Tetraspanin Function
It is unknown whether tetraspanins alter integrin conformation or affinity
for ligand. In addition, for the most part, tetraspanins do not affect static cell
adhesion. However, other integrin-dependent events—migration, spreading, and
cell morphology, among others—can be greatly affected by tetraspanins.
2.2.3.1 Cell Motility. Tetraspanins have been found to be expressed in
motility-related structures, such as lamellipodia, and involved in cell motility.
In keratinocytes, the tetraspanins CD9 and CD81 are highly expressed in
filopodia at lateral and apical surfaces, as well as in the footprints and rippings of
motile keratinocytes, suggesting a role in keratinocyte motility. In a wound
healing assay, cell migration was inhibited with antibodies to CD9 and CD81, and
to a lesser extent, to CD151, perhaps via involvement in integrin recycling during
keratinocyte migration (Penas 2000).
When HT-1080 cells are transfected with CD9, lamellipodia formation is
significantly decreased, and this effect was reversed upon antibody ligation. CD9
was able to influence lamellipodial formation by downregulating WAVE2 (Huang
2006).
In Chinese hamster ovary cells, expression of CD9 enhances cell motility
on fibronectin. This is likely via a direct interaction between CD9 EC2 and FN
(Longhurst 2002).
2.2.3.2 Tumor Cell Metastasis. Tetraspanins CD9 and CD82 are
considered metastasis suppressors in solid tumors (Wright 2004). These
tetraspanins are downregulated in progression of several cancers, including nonsmall cell lung, breast, pancreas, colon, and prostate, and decreased expression
of these tetraspanins result in poorer prognosis (Boucheix 2001, Saito 2006).
The tetraspanin CD82 (also known as KAI1) tumor metastasis suppressor
activity is believed to be through the association of CD82 with the EGF receptor
tyrosine kinase, which accelerates ligand-induced clearance of EGF receptor
from the cell surface (Bienstock 2001).
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Adenoviral transduction of CD9 or CD82 into lung tumor cells, whether via
direct implantation or through intratracheal administration, dramatically reduced
metastasis to mediastinal lymph nodes (Takeda 2007). However, overexpression of CD9 in human prostate cancer cell lines did not suppress
metastatic properties, suggesting that CD9 partner proteins may be needed for
full anti-metastatic effect (Zvieriev 2005).
2.2.3.3 Cell Proliferation and Differentiation. The tetraspanin TSSC-6
colocalizes into domains on T cells containing T cell molecules involved in T cell
stimulation, such as CD4 and CD8. Deletion of TSSC-6 yields mice with normal
lymphoid development, yet T cells showed elevated T cell receptor-dependent
proliferation in vitro in response to concanavalin A, anti-CD3, and anti-CD28
(Tarrant 2002).
Proliferation of T lymphocytes from CD81-deleted mice is also enhanced
in response to various stimuli. In B cells, deletion of the tetraspanin CD81 results
in diminished numbers of a subset of B cells (Miyazaki 1997). CD81 is also
involved in driving helper T cells toward polarized Th2 differentiation (Deng 2000,
Maecker 1997).
In the brain, deletion of CD81 results in mice with increased numbers of
astrocytes and microglia, resulting in greatly enlarged brains (Geisert 2002).
CD81 may control astrocyte and microglia proliferation in a cell-cell contactdependent manner; neurons inhibit proliferation by interacting with CD81 on
cultured astrocytes (Kelic 2001).
Tetraspanins have been implicated in growth factor signaling as well. CD9
regulates pro-TGFα, pro-HB-EGF, and pro-amphiregulin, all of which are
membrane-bound agonists for the EGF receptor (Inui 1997, Shi 2000). CD9 is
necessary for HB-EGF mitogenic activity (Nakamura 2000).
During osteoclast differentiation, CD9 expression increases during
RANKL-induced osteoclastogenesis. A CD9-neutralizing antibody suppressed
RANKL-induced multinucleated osteoclast formation and mRNA expression of
osteoclast differentiation marker genes, and this was shown to be through
regulating long-term phosphorylation of p44/42 MAPK (Yi 2006).
CD9 is also involved in megakaryocyte differentiation. In hematopoietic
stem cells, those with the highest expression of CD9 are committed to the Blymphoid or megakaryocytic lineages, and expression of CD9 is found to precede
expression of CD41 in megakaryocyte precursors. Antibody ligation to CD9
inhibited the in vitro terminal differentiation of human CD34+ cells into
megakaryocytes. It was observed that antibody ligation deeply altered membrane
structures (demarcation membranes and heterogeneous multivesicular body
membranes) of these cells (Clay 2001).
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2.2.3.4 Cellular Morphology. The tetraspanins peripherin/RDS and
ROM-1 are expressed in the retina and have specialized roles in maintaining the
outer segment discs in their characteristic flattened, parallel layers (Kohl 1998).
Point mutations in the EC2 domain are associated with various human retinal
dystrophies (Kohl 1998) and disruption of the peripherin/RDS tetraspanin gene
causes retinal degeneration (Connell 1991).
Mutation of a CD151 site influencing integrin interaction resulted in mutant
cells lacking integrin-dependent spreading and cellular cable morphology on
Matrigel (Kasarov 2002). Another mutation on CD151, affecting palmitoylation,
resulted in cells that could interact with integrins but not with other tetraspanins.
This resulted in kidney epithelial cells transitioning from a fibroblastic morphology
to an epithelial morphology (Yang 2002). A third mutation in CD151, in the Cterminal tail (abolishing a theoretical linkage to cytoskeletal or cytoplasmic
signaling molecules), altered integrin-dependent cell spreading, cellular cable
formation functions, and adhesion strengthening (Lammerding 2003, Zhang
2001).
In small cell lung cancer cells, CD9 expression is usually diminished.
Increased expression of CD9 suppressed neurite-like process outgrowth and
promoted apoptotic death. This was found to be via PI3K/Akt signaling (Saito
2006).
2.2.3.5 Virus-Induced Syncitia Formation. The tetraspanins CD9,
CD81, and CD82 have been implicated in virus-induced syncitia formation
(Fukudome 1992, Willet 1997).
In human T lymphoblasts, antibody ligation of either CD81 or CD9
enhanced syncitia formation induced by HIV-1 envelope proteins and viral entry
into the lymphoblasts. In addition, decreased CD81 and CD9 expression
increased syncitia formation and viral entry, while overexpression resulted in
decreased susceptibility to syncitia formation (Gordon-Elonso 2006).
2.2.3.6 Intracellular Vesicles. The tetraspanin web may be adapted to
facilitate vesicular fusion and fission with the cell membrane (Hemler 2003).
Tetraspanin expression is enriched in the endocytic pathway. Exosomes from B
cells are enriched for CD37, CD53, CD63, CD81, and CD82 by 7- to 124-fold
(Escola 1998). Jurkat cell activation results in CD81 removal from the cell surface
in parallel with release of CD81-containing exosomes (Fritzsching 2002).
2.2.3.7 Cell-Cell Interactions. Investigations into megakaryocyte and
proplatelet formation suggest that CD9 is involved in altering membrane
structures, suggesting a role in membrane reorganization, especially cell fusion
(Clay 2001).

29

Fluorescence microscopy has revealed that CD9, while ubiquitously
expressed across the cell membrane, is increased at areas of cell-contact,
suggesting a role in cell-cell interactions. This phenomena is observed both in
cells natively expressing CD9, such as kidney epithelium and breast cancer cells,
(Nakamura 1995, Yang 2006) and in cells that have been transfected with CD9
(Yang 2006). Additionally, CD9, CD81, and CD151, along with integrins,
accumulate at keratinocyte cell junctions (Penas 2000).
One of the most striking phenotypes of the CD9 knock-out mouse model is
the reduced fertility in females. CD9 has been shown to have a crucial role on
oocytes during sperm-egg fusion—CD9 knock-out mice oocytes are deficient in
their ability to fuse with sperm (Kaji 2000, La Naour 2000, Miyado 2000).
Furthermore, anti-CD9 antibodies can inhibit sperm-egg fusion (Chen 1999, La
Naour 2000, Miller 2000), and CD9 recombinant proteins corresponding to
residues 173-175 in CD9 EC2 partially inhibit fusion when added to the oocyte
prior to insemination but not when preincubated with sperm, showing that CD9 is
probably not a sperm receptor, but more likely influencing other members of the
tetraspanin web (Zhu 2002).
CD9 also appears to be involved in implantation, as CD9 is variably
expressed in the murine uterus depending on the stage of implantation, and was
upregulated in an ovarian steroid hormone-dependent manner (Weimin 2007).
In human ova, antibody ligation of CD9, prior to zona removal, prevented
the clustering of 61 integrin clustering and gamete fusion. Antibody ligation to
CD151 is able to partially inhibit sperm-egg fusion. This suggests that these
tetraspanins are able to control the redistribution of membrane proteins into the
clusters necessary for gamete fusion (Ziyyat 2006).
2.2.4 Tetraspanin CD9
CD9 was shown to be localized to the p region of chromosome 12 (Benoit
1991). cDNA from a megakaryocyte library showed that CD9 is comprised of
eight exons, producing a protein with 228 amino acids (Lanza 1991).
CD9 expression is most abundant on cells of megakaryocyte lineage—
megakaryocytes and platelets (Boucheix 1988, Brisson 1997, Deng 1983,
Jennings 1994). It is also expressed on macrophages (Wang 2002), eosinophils
(Fernvik 1995), basophils (Fureder 1994), marginal zone B cells (Won 2002),
endothelial cells (Barreiro 2005, Klein-Soyer 2000), ectodermal nervous tissue
(Banerjee 1997), smooth muscle cells (Scherberich 1998, Scherberich 2002),
and oocytes (Ziyyat 2006).
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CHAPTER 3 METHODOLOGY
3.1 Materials
Nonspecific mouse IgG, Fab fragment, and goat anti-mouse Fc specific
F(ab’)2 fragment were obtained from Jackson Immunolaboratories (West Grove,
PA). Adenosine 5’-diphosphate (ADP), tetramethyl rhodamine isothiocyanate
(TRITC)-labeled phalloidin, fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse antibody, fluorescein isothiocyanate (FITC)-conjugated goat antimouse Fab, nonspecific mouse IgG1, -octylglucopyranoside, and other general
reagents were purchased from Sigma Chemical Company (St. Louis, MO). FITClabeled anti-CD9 antibody, clone ML-13, was purchased from BD Biosciences
(San Jose, CA). PE-labeled anti-CD63 and anti-P-selectin were from BD
Pharmingen (San Jose, CA). Collagen was purchased from Chronolog Corp
(Havertown, PA) and TRAP (thrombin receptor agonist peptide) was purchased
from Peninsula Laboratories (San Carlos, CA). Eptifibatide was provided by
Schering-Plough (Kenilworth, NJ). Fibrinogen was from Enzyme Research
Laboratories (South Bend, IN) and fibronectin was from Gibco (Carlsbad, CA).
Gelcode Blue Stain was from Pierce (Rockford, IL) and Coomassie blue was
from BioRad (Hercules, CA). mAb7 was obtained from mouse ascites and
purified by Affi-gel Protein A column (BioRad, Hercules, CA). mFab7 was
generated and purified using Immunopure® Fab Preparation Kit (Pierce,
Rockford, IL) and purified Fab underwent buffer exchange into phosphatebuffered saline (PBS), pH 7.4, using Zeba™ Desalt Spin Columns (Pierce,
Rockford, IL). Human coagulation Factor XIII was from Calbiochem (San Diego,
CA). Vectashield mounting media was purchased from Vector Laboratories
(Burlingame, CA). Superfrost microscope slides and microscope cover glass
were from Fisher Scientific (Pittsburgh, PA). Anti-fibrinogen antibody was
obtained from The Binding Site (San Diego, CA). Protease inhibitor cocktail
tablets were from Roche (Basel, Switzerland).
3.2 Tetraspanin Expression on Resting and Activated Platelets
Flow cytometry was used to assay the levels of the tetraspanins CD9,
CD63, and CD151; the integrin GPIIb-IIIa, and the protein GPIb on the surface of
resting and activated platelets (See Fig 3.1). Blood was obtained from healthy
adult donors into 0.1 M buffered citrate as an anticoagulant. PRP was prepared
(Table 3.1) and diluted with PPP to a final platelet count of 250,000 platelets/μl.
Platelets were either allowed to remain resting or were activated with 10 μM ADP
or 2 μM TRAP. Platelets were then incubated with primary antibody for 30
minutes at 37ºC (R&D monoclonal anti-human CD151 antibody, catalog
#MAB1884 for CD151; 10E5 and 7E3 for GPIIb-IIIa; 6D1 for GPIb; BD
Pharmingen Purified mouse anti-human monoclonal antibody, catalog #3556019
for CD63; mAb7 for CD9; and mIgG, Sigma MOPC-21, as a negative control).
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Figure 3.1 Measurement of Surface Proteins by Flow Cytometry
Platelets are incubated with fluorescently-labeled antibodies which bind a specific
surface protein. Platelets are incubated with the antibody, and level of
fluorescence is measured by a flow cytometer.
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Table 3.1

Preparation of PRP and PPP

Step

Instructions

1

Whole blood is obtained by venipuncture into 0.1 M buffered citrate.
Other anticoagulants may be used as indicated. 10 ml total volume is
used per 15 ml tube.

2

Tubes are centrifuged at 135 x g for 15 minutes. Platelet-rich plasma
(PRP), the top layer, is removed and set into a clean 15 ml tube. PRP
must be carefully removed to avoid contamination with white blood
cells in the buffy coat.

3

The remaining blood is centrifuged at 2,500 x g for 15 minutes.
Platelet-poor plasma (PPP), the top layer, is carefully removed and
set into a clean 15 ml tube.

4

PRP is counted with a Coulter Counter, and diluted with PPP to the
desired concentration.
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Ten microliters of each sample were transferred to a microfuge tube with
500 μl filtered PBS+10 μl goat anti-mouse FITC-labeled antibody, and samples
were incubated for ten minutes at room temperature prior to data collection using
the flow cytometer (using the Platelet Green template). This was repeated using
ten normal, healthy adult donors.
3.3 Association of CD9 and GPIIb-IIIa in Resting and Activated Platelets
3.3.1 Co-Immunoprecipitation
Whole blood was obtained by venipuncture and mixed with ACD as an
anticoagulant (Table 3.2). Platelets were washed twice with CGS (Table 3.3),
resuspended in platelet lysis buffer containing 1% CHAPS (Table 3.4), and lysed
for 20 minutes on a rocker at 4º C. Samples were clarified by centrifugation at
18,300 x g for 10 min at 4º C, discarding the pellet. Protein concentration was
measured using Biorad Detergent-Compatible Assay kit and adjusted to 1.5
mg/ml. One ml lysate and 75 μl Protein A/G beads were added to each of five
eppendorf tubes, and samples were incubated for 60 minutes on a rocker at 4º C
and then precleared by centrifugation at 18,300 x g for one minute. Supernatants
were collected and transferred to five new tubes, to which was added either 5 μg
D3, 5 μg D3 + 3 mM eptifibatide, 5 μg AP3, 5 μg mAb7, or 5 μg mIgG (MOPC21) as a negative control. Samples were incubated with primary antibody for one
hour on a rocker at 4ºC. 75 μl Protein A/G beads were added to each tube and
incubated for 60 minutes on a rocker at 4º C. Samples were centrifuged three
times at 18,300 x g with cold lysis buffer, discarding the supernatant after each
wash. Samples were boiled with fresh non-reduced sample buffer (Table 3.5),
separated on a 5%-20% gradient separating gel (Table 3.6 and Table 3.7), and
transferred to a PVDF membrane. Membranes were blocked by rocking with 5%
nonfat dry milk in 0.1% TBS-Tween at room temperature for 60 minutes then
incubated with primary antibody in 5% nonfat dry milk in TBS-Tween overnight at
4º C (mAb7 is used to detect CD9, and C3 is used to detect IIb) (Table 3.8).
Bound antibodies are labeled with HRP-labeled sheep anti-mouse antibody and
detected with ECL-PLUS kit prior to development onto photo paper.
3.3.2 Confocal Analysis
Coverslips, in individual wells of a 20-well tissue culture plate, were coated
with 500 μg/ml FG, 50 μg/ml plasma FN, fibrin, or fibrin-FN overnight at 4ºC
(Table 3.9). Coverslips were then blocked with 1 ml 20 mg/ml BSA in PBS for 2
hours at 37ºC and washed 3x with PBS (Table 3.8). 500 μl of washed platelets
(Table 3.10), at 1x107 platelets/ml in HEPES-Tyrode buffer (Table 3.11), were
incubated 1 hour on the coverslips. Non-adherent platelets were removed by
washing 3x with HEPES-Tyrode buffer. GPIIb-IIIa was stained with D3 for 30
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Table 3.2

Anticoagulants

Material

ACD

0.1 M Buffered Citrate

Sodium citrate

0.085 M

0.06 M

Dextrose

0.1 M

---

Citric acid

0.07 M

0.04 M

Table 3.3

CGS

Material

Concentration

Sodium Citrate

0.01 M

Dextrose

0.03 M

NaCl

0.12 M

pH

6.5
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Table 3.4

Lysis Buffer for Immunoprecipitations

Amount

Material

10 mM

HEPES

200 mM

NaCl

1%

CHAPS or BRIJ-98, as indicated

5 mM

MgCl2

2 mM

NaF

100 mM

Na4P2O7

1 per 10 ml

Protease inhibitor tablet
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Table 3.5

Formula for 1/3x NR Sample Buffer

Amount

Material

1.8 ml

0.5 M Tris, pH 6.8

1.6 ml

Glycerol

0.32 g

SDS

0.32 ml

Bromophenol blue

Q.S. to 4 ml

dH2O

Table 3.6

Formulas for SDS-PAGE Gels

Material

5% Separating
Gel

20% Separating
Gel

Stacking Gel

Distilled H2O

22.5 ml

0.301 ml

6.1 ml

Glycerol

334.4 μl

1.1 ml

----

1.5 M Tris, pH 8.8

10.0 ml

5 ml

----

0.5 M Tris, pH 6.8

----

----

2.5 ml

10% SDS

401.2 μl

200.7 μl

100 μl

30%
acrylamide/bis

6.7 ml

13.4 ml

1.3 ml

TEMED

10 μl

5 μl

10 μl

10% APS (fresh)

120.3 μl

61.5 μl

50 μl
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Table 3.7

Formula for Western Blot Buffers

Material

Running Buffer

Blot (Transfer) Buffer

TRIS

18 g

12.2 g

Glycine

86.4 g

57.6 g

SDS

3.0 g

4.0 g

Methanol

----

800 ml

Total volume

3L

4L

Table 3.8

Buffered Saline Recipes

Material

Phosphate-buffered
saline (PBS)

Tris-Buffered Saline
(TBS)

Na2HPO4

0.14 M

----

NaH2PO4

0.06 M

----

NaCl

2.87 M

0.15 M

Tris

----

0.01 M

pH

7.4

7.4
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Table 3.9

Fibrin and Fibrin-Fibronectin Matrix Components

Material

Fb

FbFN

Fibrinogen

2.4 mg/ml

2.4 mg/ml

Fibronectin

0

240 μg/ml

CaCl2

0.02 M

0.02 M

NaCl

0.15 M

0.15 M

Tris-HCl, pH 7.5

0.05 M

0.05 M

Human coagulation factor XIII

5 μg/ml

5 μg/ml

Thrombin

2 units/ml

2 units/ml
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Table 3.10
Step

Preparation of Washed Platelets
Instructions

1

Whole blood is obtained by venipuncture into ACD, at a ratio of 1.4 ml
ACD to 8.6 ml whole blood. 10 ml total volume is used per 15 ml tube.

2

Blood is centrifuged at 135 x g for 20 minutes. Platelet-rich plasma,
the top layer, is removed and set into a clean 15 ml tube. PRP must
be carefully removed to avoid contamination with white blood cells in
the buffy coat. Red and white blood cells are discarded.

3

PRP is centrifuged at 800 x g for 10 minutes. The supernatant is
removed and the platelet pellet is gently resuspended in 1 ml of CGS.
This 1 ml is transferred to a fresh tube, avoiding transfer of any
platelets remaining in clumps. CGS is added to the fresh tube to bring
the volume up to 5 ml.

4

The platelet suspension is centrifuged at 800 x g for 10 minutes. The
platelet pellet is washed with CGS as in step 3.

5

After 2 washes with CGS, the pellet is resuspended in the appropriate
buffer, counted with the Coulter Counter, and diluted to the
appropriate concentration.
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Table 3.11

Modified Tyrode’s Buffer (HEPES-Tyrode Buffer)

Material

Amount

CaCl2

2 mM

BSA

0.1%

NaCl

137 mM

HEPES

20 mM

Glucose

5.6 mM

MgCl2

1 mM

NaH2PO4

3.3 mM

KCl

2.7 mM

pH

7.4
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minutes and with Sigma TRITC-labeled whole molecule goat-anti-mouse
antibody, 1:128 in PBS, for 30 minutes at room temperature. After washing with
PBS, CD9 was stained for 30 min with FITC-labeled CD9 antibody clone ML-13,
diluted 1:40 in PBS. Platelets were fixed for 30 min with 4% paraformaldehyde in
PBS and washed 3x with PBS. Coverslips were mounted with Vectashield
mounting media and edges were sealed with clear nail polish. Samples were
viewed with the confocal microscope using the 100x objective. Care was taken to
observe samples using the same settings.
3.3.3 Impact of Mutant GPIIb-IIIa
Platelets from patients with Glanzmann Thrombasthenia, featuring a
mutant GPIIb-IIIa expressed on the platelet surface, were compared with
platelets from patients with normal GPIIb-IIIa. Platelets were allowed to spread
on fibronectin or fibrin-fibronectin, and CD9 and GPIIb-IIIa were immunostained
as above. Fibronectin and fibrin-fibronectin matrices were selected due to
fibronectin being a ligand for CD9 as well as GPIIb-IIIa. It is unlikely that platelets
from patients with Glanzmann Thrombasthenia would be able to adhere or
spread on fibrinogen or fibrin matrices, as the mutated GPIIb-IIIa would likely not
be able to bind to these ligands.
3.4 Localization of CD9 during Platelet Spreading
3.4.1 Platelet-Matrix Contact
Platelets were allowed to spread as described previously. During viewing
with the confocal microscope, the upper (apical—facing away from matrix) and
lower (basal—in contact with matrix) boundaries of the platelet were selected by
focusing the microscope just above and below the regions providing a focused
view of the platelet. Usually this resulted in a 2-3 nm selection. The LSM 510
then provided slices corresponding to the apical, central, and basal sections of
the platelet, which were analyzed for CD9 and GPIIb-IIIa localization and colocalization.
3.4.2 Platelet-Platelet Contact
Platelets were allowed to spread on 500 μg/ml fibrinogen for 60 minutes in
the absence of any Fab molecules to allow maximal spreading. Platelets were
then fixed with 4.0% paraformaldehyde and permeabilized with 0.4% βoctylglucopyranoside in PHEM buffer (Table 3.12). CD9 was labeled with FITClabeled anti-CD9 antibody (clone ML-13). Samples were mounted and viewed
with a Zeiss Laser Scanning Microscope using the 100x objective.
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Table 3.12

PHEM Buffer

Material

Concentration

PIPES

60 mM

HEPES

25 mM

EGTA

10 mM

MgCl2

2 mM

pH

6.9
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Areas of platelet-platelet contact and corresponding areas of platelet periphery
not in contact with adjacent platelets were selected and pixel intensity was
quantified using the Zeiss LSM510 software.
3.4.3 Platelet Spreading Structures
To observe CD9 localization during the course of platelet spreading,
platelets were allowed to spread on 500 μg/ml fibrinogen for 5-60 minutes in the
absence of any Fab molecules. At selected time points, platelets were fixed with
4% paraformaldehyde and permeabilized with β-octylglucopyranoside in PHEM
buffer, as described above.
Platelet F-actin was labeled with TRITC-Phalloidin. CD9 was labeled with
FITC-labeled anti-CD9 antibody (clone ML-13). Samples were mounted and
viewed with a Zeiss Laser Scanning Microscope using the 100x objective. Care
was taken to visualize images using the same settings (See also Fig 2.1).
3.5 Generation and Purification of mAb7 Fab (mFab7) Fragments
3.5.1 Generation of mAb7
mAb7 was obtained from mouse ascites, purified using an Affi-gel Protein
A column, and dialyzed into PBS. Antibody concentration was assessed using an
Ultrospec 1000 UV/Visible Spectrophotometer (Pharmacia Biotech) and purity
confirmed with both nonreducing and reducing SDS-PAGE.
3.5.2 Generation of mFab7
Papain digestion of mAb7 and Fab purification was carried out using
Immunopure® Fab Preparation Kit (Pierce, Rockford, IL) (Fig 3.2). Briefly, mAb7
was incubated with immobilized papain for five hours in a 37º shaking waterbath.
The resulting digest was added to a Protein A column, allowing separation of Fab
fragments from Fc fragments and uncleaved, full-length antibody. The purified
Fab underwent buffer exchange into phosphate-buffered saline (PBS), pH 7.4,
using Zeba™ Desalt Spin Columns (Pierce, Rockford, IL). Protein concentration
was determined as above.
3.5.3 Determination of Purity and Function of mFab7
3.5.3.1 Flow Cytometry. Binding ability of mFab7 was assessed by flow
cytometry. Blood was collected by venipuncture through a 21-gauge butterfly
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Figure 3.2 Antibody Cleavage and Purification of Fab Fragment
The antibody mAb7 was cleaved by papain, resulting in an Fc and 2 Fab
fragments. The resulting digest was poured through a Protein A column, which
bound to Fc fragments and any undigested mAb7. Fab fragments (mFab7),
which did not interact with Protein A, pass through and are collected.
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needle into 0.1 M buffered citrate. Samples, per established methods, [White
1999] were centrifuged at 135 x g for 15 minutes to obtain platelet-rich plasma
(PRP). The remaining blood was centrifuged at 2500 x g for 15 minutes to obtain
platelet-poor plasma (PPP). Platelet counts were performed using a Beckman
Coulter Z2 Particle Count and Size Analyzer (Beckman Coulter, Miami, FL), and
PRP was diluted with autologous PPP to adjust the platelet count to 2.5 x 108
platelets/mL. Increasing concentrations of nonspecific Fab, mAb7 whole
molecule, or mFab7 were added to the adjusted PRP and incubated at 37° C for
30 minutes. FITC-conjugated goat-anti-mouse Fab was added and samples were
incubated at room temperature for ten minutes. Fluorescence levels were
measured using a BD FASCalibur flow cytometer with Cell Quest Pro software
(Becton Dickinson, Mountain View, CA) (see Fig 3.1).
Purity of mFab7 samples were also confirmed via flow cytometry. PRP
was prepared as above, and incubated with saturating amounts of mAb7 or
mFab7, or corresponding amounts of nonspecific IgG or IgG-Fab at 37° C for 30
minutes. FITC-labeled goat anti-mouse Fc was incubated at room temperature
for ten minutes to verify the absence of Fc fragments or intact antibody in the
mFab7 preparation. Fluorescence levels were measured as above.
3.5.3.2 SDS-PAGE. 50 μg of mFab7, mAb7, mIgG, and nonspecific
mIgG-Fab were run on both nonreducing and reducing 12% SDS-PAGE to
determine purity of mAb7 and mFab7. Gels were evaluated for bands indicating
the presence of intact antibody by Coomassie blue staining. An unknown protein
of 60 kDa was verified by mass spectrometry to be murine albumin.
3.5.3.3 Platelet Aggregation. To evaluate the ability of antibodies to
induce platelet aggregation, mAb7 (up to 20 μg/ml) or mFab7 (up to 100 μg/ml)
were added to stirring suspensions of platelets and aggregation response was
monitored for 15 minutes (Fig 3.3).
Aggregations were also performed using up to 100 μg/ml mFab7 without
inducing aggregation even after 15 minutes, while mAb7 concentrations > 0.2
μg/ml induced an aggregation response, confirming that mFab7 was functionally
greater than 98% pure.
To further ensure that the Fc receptor was not participating in the
enhanced aggregatory response, mFab7 and control Fab were pre-incubated
with a goat F(ab)’2 anti-mouse-Fc before adding to platelets, at a rate of 10
F(ab)’2 per possible intact mAb7, as calculated above.
3.6 CD9 Perturbation
Unless otherwise indicated, CD9 perturbation was carried out by preincubating platelets with 20 μg/ml mFab7 for 15 minutes at room temperature
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Figure 3.3 Light Transmission Aggregometry
Upon addition of agonist, formation of platelet aggregates is measured by
increased light transmission and tracings are recorded on a light transmission
aggregometer.
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prior to carrying out the experiment. 20 μg/ml nonspecific murine Fab was used
as a control. The control Fab was isotype-matched to mFab7 and both Fab
products were handled identically in all experiments.
3.6.1 Platelet Spreading
Fibrin-coated coverslips and fibrin-fibronectin matrix-coated coverslips
were prepared as previously described [Corbett, 1996]. Additionally, coverslips
were covered with 500 μg/ml fibrinogen or 50 μg/ml plasma fibronectin overnight.
ACD-anticoagulated blood was washed twice with CGS (0.01 M sodium citrate,
0.03 M dextrose, 0.12 M NaCl), pH 6.5, and resuspended in a modified Tyrode’s
buffer (2 mM CaCl2, 0.1% bovine serum albumin, 137 mM NaCl, 02 mM HEPES,
5.6 mM glucose, 1mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4), pH 7.4, at 2x107
platelets/ml. Platelets were incubated with 20 μg/ml mFab7 or nonspecific control
Fab and allowed to adhere and spread on coverslips for 30 minutes.
Nonadherent platelets were removed by washing with Tyrode’s buffer, and
adherent platelets were fixed with 4.0% paraformaldehyde for 30 minutes.
Platelets were permeabilized with 0.4% -ocytlglucopyranoside in PHEM buffer
(60 mM PIPES [piperazine-N,N’-bis (2-ethane sulfonic acid)], 25 mM HEPES, 10
mM EGTA, 2mM MgCl2), pH 6.9, for 5 minutes. Platelet F-actin was labeled with
TRITC-labeled phalloidin and CD9 was labeled with FITC-labeled anti-Fab
antibody. Coverslips were mounted onto slides with Vectashield Mounting Media
and edges were sealed with clear nail polish. Samples were visualized with a
Zeiss laser scanning microscope (LSM 510) using the 100x objective. Care was
taken to visualize samples using the same settings.
To quantitate pixel intensity, areas of platelet-platelet contact or
corresponding areas of the platelet periphery were highlighted and pixel intensity
(pixels per μm) was quantitated by the LSM 510 software.
3.6.2 Platelet Aggregation and Disaggregation
Platelet aggregation was measured by light transmission in a dual-channel
lumiaggregometer (Payton Scientific, Buffalo, NY) (See Fig 3.3). PRP was
preincubated with 20 μg/ml mFab7 or control Fab for 15 minutes at room
temperature. Agonist concentration was calculated as follows: ADP—the highest
concentration that would give a biphasic response in the absence of any Fabs (23 μM); Collagen—the concentration that would give a 50% response in the
absence of Fabs (0.3-1 μg/ml); TRAP—the lowest concentration that would give
a sustained response in the absence of Fabs (5-12 μM). Low concentrations of
agonist were chosen as this was the expected range to see an impact of CD9.
Following preincubation with mFab7 or control Fab, the agonist was added to the
stirring suspension of platelets, and aggregation response was recorded for 15
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minutes. The maximum aggregation response was determined for each donor,
typically at 2.5 minutes after agonist addition.
Percent platelets aggregation (%PA) was calculated at 5, 10, and 15
minutes after agonist addition. To assess platelet disaggregation, 4000 nM
eptifibatide was added to the platelet aggregates 2.5 min after agonist addition
and percent platelet disaggregation (%PD) was calculated 5, 10, and 15 minutes
after antagonist addition (Fig 3.4).
The following were used to calculate %PA and %PD:
%PA =
(number of chart divisions on the aggregometer tracing from baseline to
aggregation response at given time point)/
(total number of chart divisions representing 0% [PRP] to 100% aggregation
[PPP])
x 100;
%PD =
(%PAmax-%PAtime point)/(%PAmax)
3.6.3 Platelet Activation
PRP in citrate was prepared as described above, at 2.5x108 platelets/ml,
and preincubated with 20 μg/ml mFab7 or control Fab. Selected platelet samples
were activated with 2 μM ADP or 5 μM TRAP and incubated at room temperature
for 40 minutes. PE-labeled anti-P-selectin, anti-CD63, or nonspecific mIgG
antibodies were added to evaluate expression of P-selectin, a marker of alpha
granule release, and CD63, a marker of lysosomal release, indicating platelet
degranulation. Platelet fluorescence data, indicating surface protein expression,
were acquired using a BD FASCalibur flow cytometer with Cell Quest Pro
Software (Becton Dickinson, Mountain View, CA).
3.6.4 Fibrinogen Binding
Whole blood was drawn into buffered citrate and PRP was prepared by
centrifugation at 135 x g for 15 minutes and supernatant discarded. Pelleted
platelets were resuspended in Tyrode’s buffer (138 mM NaCl, 2.9 mM KCl, 12
mM NaHCO3, 0.4 mM MgCl2, 5.5 mM Dextrose, 0.36 mM NaH2PO4, 1.8 mM
CaCl2, pH 7.4) at 2.5x108 platelets/ml. 100 μl of platelets were incubated with 20
μg/ml mFab7 or control Fab. Platelets were incubated with 20 μM ADP or saline
control for 30 minutes at 37°C to allow binding of plasma fibrinogen. Antifibrinogen FITC antibody was added and mixed and data were acquired using a
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Figure 3.4 Eptifibatide-Induced Platelet Disaggregation
A, A platelet thrombus is maintained by fibrinogen binding and crosslinking
GPIIb-IIIa on adjacent platelets. B, Eptifibatide, a small peptide, interacts with
GPIIb-IIIa and competitively inhibits fibrinogen binding, resulting in platlelet
disaggregation. The GPIIb-IIIa antagonists abciximab and tirofiban work
similarl.y.
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BD FASCalibur flow cytometer with Cell Quest Pro software (Becton Dickinson,
Mountain View, CA).
3.6.5 Cytoskeletal Incorporation
Triton X-100-insoluble cytoskeletons of control and ADP-activated
platelets in plasma, pretreated with 20 μg/ml mFab7 or 20 μg/ml control Fab,
were prepared according to the method of Kouns et al [Kouns WC, 1991]. Briefly,
PRP in citrate were prepared at 3x108 platelets/mL. After pretreatment with Fab,
2 μM ADP was added to stirring platelet suspension at 37°C. After five minutes,
samples were rapidly removed and lysed with ice-cold 2% Triton lysis buffer (100
mM Tris-HCl, 10 mM EGTA, 2% Triton X-100, 2 mM 2-mercaptoethanol, and
protease inhibitor cocktail tablet; Table 3.13) and lysates were kept on ice.
Platelet lysates were centrifuged at 4°C at 15,600 x g to isolate the platelet
core cytoskeleton. The resulting samples were denatured and electrophoresed
on a 5-20% SDS-polyacrylamide exponential gradient gel overnight. Proteins
were visualized by staining with Coomassie Blue. Densitometry was performed
by photocopying each gel, and carefully removing and weighing each band with a
Sartorius Research quantitative electric balance (Sartorius Research,
Goettingen, Germany).
3.6.6 Akt Phosphorylation
3.6.6.1 During Platelet Aggregation. PRP was prepared from whole
blood and adjusted to 3x108 platelets/ml with PPP. Samples were pretreated with
saline, control Fab, or mFab7 for 15 minutes at room temperature, then
monitored with a lumiaggregometer for five minutes upon addition of 2 μM ADP
or saline. Samples were then centrifuged, and pellets were collected, denatured,
and subjected to electrophoresis on a 5-20% gradient SDS-PAGE. Proteins were
transferred to a PVDF membrane, blocked with 5% BSA in TBS-Tween, and
incubated with an anti-phospho-Akt antibody overnight on a rocker at 4ºC. The
primary antibody was labeled with a secondary donkey anti-rabbit-HRP antibody
for 60 minutes in the presence of 5% BSA in TBS-Tween. Membranes were
developed using the ECL-PLUS kit and stored in PBS at 4ºC until continuing with
stripping. To strip, membranes were completely submerged in Restore Western
Blot Stripping Buffer and agitated for 15 minutes at 37ºC. After washing with
TBS-Tween, western blotting was continued with an anti-Akt (total) antibody.
Alternatively, the antibody 4G10 was used in place of anti-phospho-Akt antibody,
to measure total protein tyrosine phosphorylation.
3.6.6.2 Without Stirring or Aggregation. PRP was prepared from
whole blood and adjusted to 3x108 platelets/ml with PPP. 500 μl samples were
treated with saline, control Fab, or mFab7 in eppendorf tubes for 15 minutes at
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Table 3.13

Cytoskeletal Extraction Buffers, pH 7.4

Reagent

2% Triton X-100
Extraction Buffer

Triton-free Wash Buffer

Tris-HCl

100 mM

100 mM

EGTA

10 mM

10 mM

Triton X-100

2%

----

2-mercaptoethanol

2 mM

2 mM

Protease Inhibitor Tablet

1 per 10 ml

1 per 10 ml
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room temperature, then treated with saline or 2 μM ADP. After addition of each
treatment, the suspension was carefully and slowly brought up and down twice in
a pipette to gently mix. After a five minute incubation, the samples were
centrifuged in a pre-cooled microcentrifuge and pellets were washed twice with
ice-cold saline.
Samples were denatured with reducing sample buffer and
electrophoresed on a 5-20% gradient SDS-PAGE. Samples were transferred to a
PVDF membrane, which was incubated overnight on a rocker at 4ºC with antiphospho-Akt antibody. After generous washing with TBS-Tween, Akt was labeled
with donkey anti-rabbit HRP, and 4G10 was labeled with goat anti-mouse HRP.
Membranes were developed with ECL-PLUS kit and stored in PBS until
continuing with stripping. To strip, membranes were completely submerged in
Restore Western Blot Stripping Buffer and agitated for 15 minutes at 37ºC.
After washing with TBS-Tween, western blotting was continued with an anti-Akt
(total) antibody.
3.6.7 Tetraspanin Web Organization
Whole blood was obtained by venipuncture using ACD as an
anticoagulant. Platelets were washed twice with CGS and resuspended at
250,000/mm3 in ACD. After pretreatment with 20 μg/ml mFab7 or control Fab for
15 minutes at room temperature, platelets were activated with 2 μM ADP or
allowed to remain in a resting state. Samples were removed for flow cytometric
evaluation of CD63 and P-selectin on the platelet surface to verify platelet
activation. Platelet samples were then resuspended in 1% Brij-98 lysis buffer and
lysed overnight on a rocker at 4ºC. Samples were clarified by centrifugation at
18,300 x g for 10 minutes at 4ºC and the pellet was discarded. Protein
concentration was detected using the Biorad Detergent-Compatible Assay kit and
protein concentration adjusted to 1.5 mg/ml.
Samples were precleared with Protein A beads, centrifuged, and the
supernatant transferred to a clean tube. Samples were then incubated for one
hour at 4ºC with mIgG as a control or with 10E5, an antibody that binds the
GPIIb-IIIa complex regardless of activation conformation. Samples were then
incubated with Protein A beads overnight on a rocker at 4ºC.
Immunoprecipitation complexes were separated on a 5-20% reducing
SDS-PAGE and transferred to a PVDF membrane. After the transfer, the
membrane was cropped from 15 kDa to 35 kDa to probe for CD9 (mAb7); from
35 kDa to 75 kDa to probe for CD63 (BD anti-CD63); and from 75 kDa to above
160 kDa to probe for GPIIb-IIIa (C3). Probing occurred overnight at 4ºC. Primary
antibodies were then labeled with HRP-conjugated Sheep anti-mouse antibody in
TBS-Tween + 5% nonfat dry milk and images developed with ECL-PLUS kit.
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3.6.8 Clot Retraction
Whole blood was obtained by venipuncture using 0.1 M buffered citrate as
an anticoagulant. PRP was obtained and diluted with PPP to obtain platelets at
either 250,000/mm3 or 100,000/ mm3. After 15 minutes incubation in eppendorf
tubes with 20 μg/ml mFab7, 20 μg/ml control Fab, corresponding volume of
saline, or 20 μg/ml D3 (as a positive control) samples were transferred to 12 x 75
glass tubes. CaCl2 was added to each tube, samples were mixed by flicking, and
each tube was capped and incubated in a 37 ° C waterbath. Tubes were
observed every 15 minutes until retraction was complete.
3.7 Statistical Significance
Values are reported as mean ± standard deviation as calculated by
Microsoft Excel (Microsoft Corporation, Seattle, WA). T-tests were performed
using Microsoft Excel. Results of cytoskeletal incorporation and aggregation with
recombinant proteins were evaluated using ANOVA (Boneferroni test) with
Sigma stat software.
Results are expressed as percentages ± standard deviation. p value of
≤0.05 was accepted as statistically significant.
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CHAPTER 4 RESULTS
4.1 Tetraspanin Expression on Resting and Activated Platelets
The surface expression levels of CD9, the tetraspanins CD63 and CD151,
and the tetraspanin-associated proteins GPIb and GPIIb-IIIa (integrin αIIbβ3) was
evaluated in platelets that were either allowed to remain resting or were activated
with 10 μM ADP or 5 μM TRAP (Fig 4.1A). Although TRAP is a more potent
agonist than ADP, these concentrations should induce platelet activation,
including granule release.
Although CD9 has been characterized as a member of alpha granules
(Brisson 1997, Cramer 1994), the surface expression of CD9 in resting platelets
(mean fluorescence intensity (MFI) = 183.2 ± 28.7) versus ADP- (236.4 ± 25.8) or
TRAP-activated (229.0 ± 30.3) platelets was not statistically significantly different.
The lack of statistical significance may be due to the wide range of CD9
expression among individual donors, as each donor showed an increase in CD9
surface expression upon activation, particularly with ADP (Fig 4.1B).
As expected, resting platelets did not express CD63 (MFI = 8.2 ± 1.3,
compared to background control mIgG (MFI = 8.0 ± 1.0). CD63 expression was
detected upon ADP activation (16.5 ± 3.2) and TRAP activation (27.7 ± 5.9). The
increase in CD63 expression was statistically significant in activated vs. resting
platelets (p<0.05), but not between ADP and TRAP activation (p>0.05).
CD151 was detected on the surface of resting platelets (MFI = 24.6 ± 2.5),
and was statistically significantly increased by ADP activation (MFI = 42.4 ± 2.8,
p ≤ 0.01 compared to resting) or by TRAP activation (MFI = 46.2 ± 3.4, p ≤ 0.01).
GPIIb-IIIa surface expression was detected by the antibody 10E5. This
antibody binds to the GPIIb-IIIa complex, and has an equal affinity for both the
active and inactive conformation of GPIIb-IIIa, so integrin activation following
platelet activation will not alter detection of surface expression. GPIIb-IIIa was
detected on the surface of resting platelets (MFI = 129.6 ± 11.0), and was
statistically significantly increased by activation by ADP (MFI = 218.5 ± 15.8,
p<0.01) or TRAP (MFI = 214.4 ± 13.8, p<0.01).
GPIb, part of the GPIb-IX-V complex, was also detected on the surface of
resting platelets (MFI = 84.5 ± 4.5). Its level was increased to 117.2 ± 7.7 by ADP
activation and to 103.9 ± 7.3 by TRAP activation. The difference between resting
and ADP-activated platelets was statistically significant (p<0.01), but the
difference between resting and TRAP-activated platelets was not statistically
significant (p>0.05). This slight decrease following TRAP activation, compared to
ADP activation, may be due to this receptor shedding its alpha subunit following
potent activation (Bergmeier 2004).
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Figure 4.1 Expression of Tetraspanins on the Platelet Surface
A, Platelet surface expression of CD9, CD151, CD63, GPIIb-IIIa, and GPIb under
resting conditions or activated with ADP or TRAP, as measured by flow
cytometry. mIgG provides a negative background control. CD9 does not show a
statistically significant increase in expression upon platelet activation. CD151,
CD63, and GPIIb-IIIa display a statistically significant increase in expression
upon platelet activation, whether by ADP or TRAP. GPIb displays an increase in
surface expression upon mild activation by ADP, but not a statistically significant
increase upon stronger activation by TRAP. B, mAb7 binding to resting or
activated platelets of individual donors. *, p<0.05; **, p<0.001; n=5.
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4.2 Association of CD9 and GPIIb-IIIa in Resting and Activated Platelets
4.2.1 Co-Immunoprecipitations
Immunoprecipitations were performed using 1% CHAPS, a mild detergent
which does not disrupt the integrity of the tetraspanin web. The platelet lysate
was either immunoprecipitated with mIgG, a nonspecific antibody; mAb7, a CD9
EC2 antibody; or D3, a GPIIb-IIIa antibody (Fig 4.2). D3 was used in the
presence or absence of eptifibatide to evaluate the effect of receptor occupancy
on CD9-GPIIb-IIIa interactions.
After protein separation by SDS-PAGE, a denaturing polyacrylamide gel
electrophoresis, immunoprecipitates were probed for CD9 or GPIIb (a component
of GPIIb-IIIa). D3 was found to immunoprecipitate GPIIb, with no difference upon
inclusion of eptifibatide. D3 also co-immunoprecipitated a portion of CD9, with no
difference upon inclusion of eptifibatide. Conversely, mAb7 was able to
immunoprecipitate CD9 and co-immunoprecipitate a portion of GPIIb. The
negative control, mIgG, was not able to immunoprecipitate either protein,
confirming antibody specificity.
These results indicate that a portion of CD9 and GPIIb-IIIa associate with
each other in the membrane, and that this interaction is maintained with 1%
CHAPS. Integrin binding to eptifibatide does not appear to alter the association
between CD9 and GPIIb-IIIa, suggesting that the association between CD9 and
GPIIb-IIIa may be controlled by another mechanism besides ligand binding to the
integrin.
4.2.2 Confocal Analysis
Platelets were allowed to spread on four matrix substrates: FG, FN, FbFN, or Fb (Fig 4.3). All of these matrix proteins are ligands for GPIIb-IIIa, and FN
is additionally a ligand of CD9. After 60 minutes, most adherent platelets were
fully spread, although there were some platelets just extending filopodia or
lamellipodia. At this concentration, some platelets did not contact other platelets,
while other platelets were in direct physical contact with adjacent platelets.
On all matrices, CD9 was most intense at platelet-platelet contacts.
Additionally, CD9 was pronounced at the platelet periphery, within the extended
filopodia and lamellipodia, and centralized at discrete points in the platelet body
(potentially where granules were clustered).
The matrices displayed some modest differences in CD9 distribution.
CD9 localization on fibrin or fibrin-FN was more diffuse, with increased signal
across the entire surface of the platelet compared to FG or FN.
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Figure 4.2 Co-Immunoprecipitation of CD9 and GPIIb-IIIa
A, GPIIb is detected in samples immunoprecipitated with the CD9 antibody
mAb7, as well as the GPIIb-IIIa LIBS antibody D3 in the presence or absence of
4000 nM eptifibatide. B, CD9 is deteted in samples immunoprecipitated with
mAb7, and a fraction of C9 is co-immunoprecipitated with D3. Coimmunoprecipitation is not altered by the presence of 4000nM eptifibatide. mIgG
is not able to precipitate GPIIb or CD9.
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Figure 4.3 Localization of CD9 and GPIIb-IIIa in Spread Platelets
CD9 staining by ML13-FITC is similar in platelets spread on either FG or FN.
CD9 can be found across the entire platelet surface, but is most intense at the
platelet periphery or in filopodia. There is also an increased level of CD9 at
platelet-platelet contact sites. GPIIb-IIIa staining by D3-TRITC on both matries is
concentrated on the periphery of the spread platelets. Staining is also present in
platelet centers. Colocalization between CD9 and GPIIb-IIIa is found at the
platelet periphery. Colocalization is also found at platelet-platelet contact sites in
platelets spread on FG. In platelets spread on fibrin, CD9 localization is diffuse
across the entire platelet surface. In platelets spread on fibrin, CD9 localization is
diffuse across the entire platelet surface. In platelets spread on fibrin-FN, the
CD9 localizaiton appears as an intermediate between platelets spread on fibrin.
On both matrices, colocalization is found at the platelet-platelet contact sites.
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GPIIb-IIIa also tended to be most intense at the platelet periphery and
platelet centers. GPIIb-IIIa was most diffuse in platelets spread on fibrin. There
was extensive co-localization between CD9 and GPIIb-IIIa in spread platelets on
all matrices. Co-localization was most pronounced at the platelet periphery and
at platelet-platelet contacts. This suggests that CD9 plays an important role in
modulating GPIIb-IIIa adhesive functions at platelet-platelet contacts and in
platelet spreading. CD9 may alter the conformation of GPIIb-IIIa at these areas,
or may be modulating the presentation of ligand to integrin.
4.2.3 Impact of Mutant GPIIb-IIIa
Platelets from patients with Glanzmann Thrombasthenia, expressing
mutant GPIIb-IIIa on the surface that is incapable of binding ligand, were able to
bind and spread on fibronectin and fibrin-fibronectin (Fig 4.4). The platelet
adhesion and spreading ability may be due to other platelet integrins, to CD9, or
to a possible unaffected ligand binding site on GPIIb-IIIa. Interestingly, a subset
of the platelets expressing the mutant GPIIb-IIIa exhibited abnormal platelet
spreading on both matrices—they spread over a larger surface area on fibrin,
and over a smaller surface area on fibrin-fibronectin, compared to normal
controls.
Although co-localization analysis is difficult to perform due to the
diminished GPIIb-IIIa staining, it appears that the expressed GPIIb-IIIa exhibits
localization and CD9 colocalization similar to normal platelets.
In the platelets expressing mutant GPIIb-IIIa, flow cytometric analysis
demonstrated that CD9 expression was increased (data not shown). This could
be due to attempted compensation, as CD9 is believed to be a receptor for
fibronectin and could attenuate the impact of mutated GPIIb-IIIa. However, it is
also possible that the mutation of GPIIb-IIIa alters the CD9-GPIIb-IIIa association
to such an extent that there is better access for antibody binding.
4.3 Localization of CD9 during Platelet Spreading
4.3.1 Platelet-Matrix Contact
Slices of spread platelets were viewed independently of other slices above
or below the desired plane using the confocal microscope (Fig 4.5). Platelets
were sliced into three sections: the basal section included the segment of the
platelet in contact with the matrix; the apical section was the upper third of the
platelet facing away from the matrix; and the central section comprised the
portion of the platelet between these two sections.
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Figure 4.4 CD9 Localization in Glanzmann Thrombasthenia
A, Comparison of normal and GT platelets spread on FN. B, Comparison of
normal and GT platelets spread on Fb-FN. Green, CD9 ; Red, GPIIb-IIIa ; Yellow,
merge. Note that GPIIb-IIIa mutation does not alter platelet adhesion nor the
colocalization etween CD9 and GPIIb-IIIa ; however, extent of platelet spreading
is altered, with platelets spreading more on Fb and less on Fb-FN compared to
normal controls.

61

Apical

Central

Basal

FG

FN

Fibrin

Fibrin-FN

Figure 4.5 Analysis of CD9 Localization in Platelet Sections with or
without Matrix Contact
GPIIb-IIIa (D3-TRITC, red) is localized in the basal portion of the platelet (in
contact with the matrix). Much lower GPIIb-IIIa levels are observed in the apical
sections of the platelet. CD9 (ML13-FITC, green) is found in the apical and
central sections of the platelet, but only a low level of expression is observed in
contact with matrix. Co-localization (yellow) between CD9 and GPIIb-IIIa is found
mainly at the platelet-platelet contact sites. There is only a low level of CD9 and
GPIIb-IIIa colocalization at platelet-matrix contact sites on the basal portion of the
platelet. Additionally, only a low level of colocalization is observed at the apical
sections of the platelets.
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GPIIb-IIIa expression was found to be intense in the basal section, where
platelets were in contact with the matrix. GPIIb-IIIa was also found at regions of
platelet-platelet contact in the basal and central sections. Surprisingly, there was
very little CD9 expression observed in the basal section of the platelets on any of
the matrices. This indicates that CD9 does not likely have an important role in
direct adhesion to the matrix—even to fibronectin, a known ligand—or to
modulating GPIIb-IIIa adhesion to the matrix. However, the expression of CD9 in
spreading structures such as filopodia and lamellipodia suggests a role for CD9
in platelet spreading events. CD9 expression was intense in the central region of
the platelet, where it was strongly colocalized with GPIIb-IIIa, particularly at
platelet-platelet contact sites. This further indicates a likely involvement of CD9 in
modulating the role of GPIIb-IIIa in platelet-platelet interaction and thrombus
stability.
Only low levels of CD9 or GPIIb-IIIa were observed in the apical sections
of platelets. This is not unusual, as both proteins would be expected to be
localized to sections of the platelet membrane involved in contact with platelets
or matrix.
4.3.2 Platelet-Platelet Contact
When platelet spreading resulted in platelet-platelet contact, CD9 staining
was greatly intensified at these contact points (pixel intensity = 141.5 ± 8.9)
compared to the platelet periphery not involved in platelet-platelet contact (pixel
intensity = 32.7 ± 16.2) (Fig 4.6). It is evident that CD9 is being actively localized
into areas of platelet-platelet contact, and not merely an additive effect, as the
intensity at platelet-platelet contact is more than double the intensity at noncontact periphery.
4.3.3 Platelet Spreading Structures
The localization of CD9 was initially characterized in platelets throughout
the stages of adhesion and spreading on fibrinogen, as well as its colocalization
with F-actin, using confocal microscopy (Fig 4.7). Immediately upon adhesion to
fibrinogen, platelets developed a rounded shape, with CD9 distributed throughout
the entire platelet surface. CD9 was colocalized with F-actin as evidenced by the
yellow merge signal. As the platelet began extending filopodia and lamellipodia,
CD9 was increasingly localized to these extensions. Co-localization with F-actin
was still observed, although the degree of co-localization was decreased as
platelet spreading proceeded. As the platelet progressed to a fully spread
morphology, CD9 was distributed evenly across the platelet membrane; however,
after 60 minutes, a large portion of CD9 localized in punctate clusters at the
leading edge of the platelet. Co-localization of CD9 and F-actin was no longer
evident.
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Figure 4.6 Localization of CD9 at Platelet-Platelet Contacts
A, CD9 staining is intensified at areas of contact between spread platelets (red
arrowheads). B, Quantitation of pixel intensity at platelet-platelet contacts vs. the
platelet periphery not involved in platelet-platelet contacts. These data indicate
that CD9 is actively localized at platelet-platelet contacts, and that the
observation is not due to the additive effect of multiple platelet membranes in
contact. **, p<0.01. n=4.
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Figure 4.7 Localization of CD9 and Actin during Platelet Spreading
Washed platelets in progressive stages of platelet spreading. In newly adherent,
round platelets, CD9 (ML13-FITC) covers the platelet surface. There is a high
level of colocalization with F-actin (Phalloidin-TRITC). As the platelet extends
filopodia and lamellipodia, CD9 is highly expressed in these areas. The level of
CD9 and actin co-localization appears to diminish as the platelet proceeds
through the spreading process. In a nascent, spread platelet, the CD9 is found
across the platelet membrane but is most strongly expressed at the platelet
periphery. As platelets are allowed to spread for 60 minutes, CD9 localizes to
discrete, punctuate areas on the platelet periphery, although there is still CD9
localized across the entire platelet surface. n=4.
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4.4 Generation and Purification of mAb7 Fab (mFab7) Fragments
To evaluate the role of CD9 independently from the platelet FcRII
receptor, Fab fragments were created from the monoclonal antibody mAb7, an
antibody with a high affinity for CD9 EC2. This antibody was chosen due to its
functional effects in smooth muscle cells (unpublished data) as well as its
functional effects in CHO cells transfected with human GPIIb-IIIa (Cook 1999).
Upon cleavage with papain and passage through a Protein A column, the
isolated Fab fragments, henceforth designated mFab7, along with intact mAb7
and control mIgG and control mIgG Fab fragments, were electrophoresed
reduced and nonreduced through SDS 5-20% polyacrylamide gradient gels.
Protein staining by Gelcode Blue showed a homogeneous preparation with no
detectable intact mAb7 even with > 50 μg Fab protein loaded onto the gel (Fig
4.8A). The contaminant band of approximately 60 kDa in mAb7 and mFab7 lanes
was excised and subjected to mass spectrometry. This protein was identified as
murine albumin (data not shown).
As intact mAb7 can induce platelet aggregation, aggregation tracings were
recorded with mAb7 and mFab7 to verify that mFab7 was purified, without any
traces of intact antibody. Aggregations performed using up to 100 μg/ml mFab7
did not induce aggregation even after 15 minutes, while mAb7 concentrations >
0.2 μg/ml induced an aggregation response (Fig 4.8B). Therefore, from a
functional perspective, the mFab7 was virtually free of intact, functional mAb7.
A FITC-labeled, goat anti-mouse-Fab antibody was used to verify binding
competency of mFab7 under flow cytometry. Mean fluorescence intensity (MFI),
measuring binding of anti-Fab to mAb7 and mFab7, was 92.45 and 112.84,
respectively, indicating Fab7 binding was similar to that of the intact mAb7
antibody (Fig 4.8C). When a FITC-labeled goat anti-mouse-Fc antibody was
used, the MFI for the mAb7 sample was 108.58 as expected, while the MFI of the
mFab7 sample was reduced to control mouse levels, further indicating that the
mFab7 sample was free of intact mAb7 (Fig 4.8D).
4.5 CD9 Perturbation
4.5.1 Platelet Spreading
Human platelets were pre-incubated with either control isotype-matched
Fab (control) or mFab7 then allowed to spread on one of four matrices—
fibronectin (FN), fibrin (Fb), Fb-FN cross-linked matrix, or fibrinogen (FG)—all
four of which are ligands for GPIIb-IIIa, the major platelet integrin, and are
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Figure 4.8 Purification of mFab7 from mAb7
A, mAb7 digests on a non-reducing or reducing SDS-PAGE. Lane 1, undigested
control mIgG; lane 2, control Fab; lane 3 undigested mAb7; lane 4, mFab7; 50 μg
protein per lane. B, mAb7 causes platelet aggregation when added to a stirring
suspension of platelets, but mFab7 does not cause platelet aggregation. C, Flow
cytometric analysis indicates mFab7 binding ability on the platelet surface. D,
Flow cytometric analysis reveals that an anti-Fc antibody does not bind to
platelets with mFab7, further indicating purity.
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Figure 4.8 (continued)
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exposed to platelets as components of plasma, atherosclerotic plaques, or at
sites of vascular injury.
Pre-incubation with mFab7 did not appear to alter the localization or
staining pattern of CD9 or F-actin, but it increased the stage of spreading of
platelets on all four matrices (Fig 4.9). When platelets on Fb were quantified
based on stage of spreading, it was found that platelets were in the early stages
of platelet spreading—either newly adherent or extending filopodia—when they
were preincubated with control Fab (p<0.05), whereas platelets treated with the
mFab7 were more likely to be fully spread. Similarly, platelets on FN, Fb-FN, or
FG were adherent or extending filopodia when pretreated with control Fab
(p<0.05), but were extending lamellipodia or fully spread when pretreated with
mFab7.
Interestingly, treatment with mFab7 increased the total number of
adherent platelets on Fb-FN per frame (p<0.05), but this treatment led to no
difference in the total number of adherent platelets per frame on the other
matrices.
Additionally, mFab7 decreased the relative amount of actin co-localizing
with CD9 on FbFN (62 ± 12% with control Fab vs 30 ± 6% with mFab7) and on
FG (45 ± 7% with control Fab vs 24 ± 7% with mFab7) (Fig 4.10), but a change
was not statistically significant on FN or Fb. A decrease in colocalization is likely
because mFab7 treatment enhances platelet spreading, and a normal decrease
in CD9-actin colocalization is observed as platelets spread more fully.
4.5.2 Platelet Aggregation and Disaggregation
MFab7 also increased the aggregation of platelets in response to low
concentrations of ADP (2-3 μM) or collagen (0.6-1.0 μg/ml) (Fig 4.11 and Table
4.1). In response to threshold ADP, the control sample exhibited a mean maximal
aggregation of 54.3 ± 5.0%, which then decreased to 43.7 ± 4.7%, 26.7 ± 4.0%,
and 20.0 ± 2.0% after 5, 10, and 15 minutes, respectively. When mFab7 was
used, the maximal aggregation is 73.7 ± 7.5%, and the aggregate is more stable,
with 70.7 ± 12.7%, 64.7 ± 16.3%, and 59.3 ± 15.5% aggregation for 5, 10, or 15
minutes after addition of agonist. When threshold levels of collagen were used,
the results were similar: for control-treated platelets, the percent aggregation is
62.0 ± 10.4%, 60.3 ± 13.3%, 52.0 ± 14.9%, and 44.7 ± 14.1%, respectively, for
maximal aggregation, and 5, 10, or 15 minutes after addition of agonist. For
mFab7-treated platelets, this increased to 72.3 ± 3.1%, 72.3 ± 3.1%, 68.0 ±
2.6%, and 62.3 ± 2.1%, respectively. When platelets were activated by threshold
levels of Thrombin Receptor Agonist Peptide (TRAP, 5-10 μM), mFab7 did not
increase the aggregation: 72.3 ± 7.6%, 71.3 ± 8.7%, 65.3 ± 13.6%, and 58.7 ±
15.3% for control vs. 72.7 ± 9.7%, 71.7 ± 11.7%, 66.7 ± 14.0%, and 61.0 ± 14.9%
for mFab7 (Fig 4.11C and Table 4.1).
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Figure 4.9 CD9 Affects Platelet Spreading on Fibronectin (FN), Fibrin (Fb),
Fibrin-Fibronectin Matrix (Fb-FN), or Fibrinogen (FG)
A,Quantification of platelets throughout stages of platelet spreading. B, Confocal
microscopy images show platelets that are incubated with 20 μg/ml mFab7 (right)
exhibit greater spreading on all matrices than platelets that are incubated with 20
μg/ml of a nonspecific control Fab. Localization of CD9 does not appear to be
altered by mFab7 binding. C, Zoom of Merge view from B. *, p<0.05. **, p<0.01.
n=5.
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Figure 4.10 Impact of CD9 Perturbation on Colocalization with F-actin
CD9 perturbation with mFab7 results in decreased levels of F-actin (as
measured by TRITC-phalloidin) co-localizing with CD9 (as measured by
ML13-FITC) in platelet spreading on FbFN and on FG. Perturbation does not
lead to statistically significant changes in colocalization in platelets spread
on Fb or on FN. n=5. **, p<0.01.
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Figure 4.11 CD9 Affects Platelet Aggregation
A, Platelets activated by ADP. Preincubation with mFab7 results in a significant
increase in percent aggregation at all time points compared to preincubation with
control Fab. B, Platelets activated by collagen. Preincubation with mFab7 results
in a significant increase in percent aggregation at maximum aggregation and at
10 and 15 minutes after addition of collagen. C, Platelets activated by thrombin
receptor agonist peptide (TRAP). Preincubation with mFab7 does not alter
platelet aggregation. max, maximum aggregation after addition of agonist.
*, p<0.05. **, p<0.01. n=4.
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Table 4.1. Perturbation of CD9 Affects Percent Platelet Aggregation1
Agonist

Fab

Max
5 min
aggregation

10 min

15 min

ADP

mFab7
control Fab

73.7 ± 7.5
54.3 ± 5.0

70.7 ± 12.7
43.7 ± 4.7

64.7 ± 16.3
26.7 ± 4.0

59.3 ± 15.5
20.0 ± 2.0

Collagen

mFab7
control Fab

72.3 ± 3.1
62.0 ± 10.4

72.3 ± 3.1
60.3 ± 13.3

68.0 ± 2.6
52.0 ± 14.9

62.3 ± 2.1
44.7 ± 14.1

TRAP

mFab7
control Fab

72.7 ± 9.7
72.3 ± 7.6

71.7 ± 11.7
71.3 ± 8.7

66.7 ± 14.0
65.3 ± 13.6

61.0 ± 14.9
58.7 ± 15.3

1

Percent platelet aggregation, showing the maximum aggregation achieved, and
percent aggregation at 5, 10, and 15 minutes after addition of agonist, ± standard
deviation.
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Eptifibatide, a GPIIb-IIIa antagonist, is also used in conjunction with these
agonists to evaluate platelet disaggregation. The addition of eptifibatide to
platelet aggregates enhances the rate and extent of disaggregation of platelet
aggregates by displacing bound fibrinogen to the activated GPIIb-IIIa receptor.
The ability of eptifibatide to increase the rate and extent of platelet
disaggregation was decreased by treatment with mFab7 with all three agonists
studied (Fig 4.12 and Table 4.2); however, the effect of eptifibatide was not
totally blocked. When threshold ADP was the agonist, percent aggregation at 5,
10, and 15 minutes after addition of eptifibatide was 38.3 ± 2.1%, 23.7 ± 2.5%,
and 19.3 ± 2.3%, respectively, for control-treated platelets, and 57.3 ± 5.1%, 44.7
± 6.1%, and 38.7 ± 6.7%, respectively, for mFab7-treated platelets. When
threshold collagen was the agonist, the percent aggregation for control-treated
platelets was 31.0 ± 19.1%, 27.0 ± 17.4%, and 24.6 ± 16.7%, respectively, while
for mFab7-treated platelets it was 62.3 ± 8.1%, 57.0 ± 9.8%, and 53.3 ± 11.2%,
respectively. mFab7 even exerted an effect on disaggregation when TRAP was
used as the agonist: percent aggregation was 45 ± 18.1%, 33.7 ± 15.3%, and
29.0 ± 13.0% with control-treated platelets, and 63.3 ± 1.5%, 51.3 ± 3.1%, and
46.3 ± 2.1% for mFab7-treated platelets.
Additionally, mFab7 and control Fab were pre-incubated with a goat
F(ab)’2 anti-mouse-Fc before adding to platelets, at a rate of 10 F(ab)’2 per
possible intact mAb7, as calculated above. Although the F(ab)’2 slightly
decreased aggregation, the mFab7 still exhibited increased aggregation and
thrombus stability compared to the control Fab.
The results from these experiments led to the hypothesis that CD9 may
indeed serve as a link to integrin activation and its function may serve as a
tipping point for platelet reactivity. Further examination of GPIIb-IIIa function,
such as fibrinogen binding, was measured with or without Fab treatments.
4.5.3 Platelet Activation
Platelet activation was assessed by detection of CD63 and P-selectin
(CD62) via flow cytometric analyses (Fig 4.13). Resting platelets, in the absence
of agonist, did not have a statistically significant difference in the measurement of
either CD63 or P-selectin between control- and mFab7-treated platelets.
However, when platelets were activated by threshold levels of ADP (2 μM),
mFab7 treatment increased the expression of both CD63 and P-selectin: the MFI
for control-treated platelets was 33.3 ± 0.2 for P-selectin and 14.1 ± 3.0 for
CD63, while for mFab7-treated platelets the MFI was increased to 91.1 ± 14.8 for
P-selectin and 25.6 ± 3.3 for CD63. Interestingly, mFab7 did not increase the
expression of either protein when platelets were activated with threshold TRAP
(10 μM). Future studies can be performed to determine the optimal concentration
of TRAP for mFab7 to amplify the signal.
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Figure 4.12 CD9 Affects Eptifibatide-Induced Platelet Disaggregation
4000 nM eptifibatide is added to agonist-activated platelets at the point of
maximum aggregation (2.5 min after addition of agonist). Incubation with mFab7
results in more stable aggregates with all agonists tested. A, ADP; B, Collagen;
C, TRAP. *, p<0.05; **, p<0.01. n=4.
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Table 4.2. Perturbation of CD9 Affects Eptifibatide-Induced Platelet
Disaggregation2
Agonist

Fab

Max
aggregation

5 min

10 min

15 min

ADP

mFab7
control Fab

69.4±4.0
63.3±4.5

57.3±5.1
38.3±2.1

44.7±6.1
23.7±2.5

38.7±6.7
19.3±2.3

Collagen

mFab7
control Fab

72.7±3.7
59.3±8.0

62.3±8.1
31.0±19.1

57.0±9.8
27.0±17.4

53.3±11.2
24.6±16.7

TRAP

mFab7
control Fab

74.7±0.6
68.7±4.5

63.3±1.5
45±18.1

51.3±3.1
33.7±15.3

46.3±2.1
29.0±13.0

2

Percent platelet aggregation, showing the maximum aggregation achieved, and
percent aggregation at 5, 10, and 15 minutes after addition of eptifibatide, ±
standard deviation.
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Figure 4.13 CD9 Affects Platelet Activation
Pre-incubation with 20 μg/ml mFab7 increases P-selectin (CD62P) and CD63
expression on platelets activated with 2 μM ADP, compared to platelets preincubated with 20 μg/ml nonspecific control Fab. mFab7 did not affect P-selectin
or CD63 expression on platelets that were activated with 10 μM TRAP or on
platelets that were not activated by agonist. **, p<0.01. n=5.
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4.5.4 Fibrinogen Binding
In the absence of agonist stimulation, platelets bound a low level of
fibrinogen, with no difference between control Fab-treated platelets and mFab7treated platelets (mean MFI = 48.06 ± 22.3 and 48.13 ± 22.5, respectively) (Fig
4.14). When platelets were activated without stirring by 2 μM ADP, the binding of
fibrinogen increased slightly (MFI = 70.13 ± 5.4). The most notable increase in
fibrinogen binding occurred when platelets treated with mFab7 and activated by
ADP (MFI = 122.1 ± 15.9). The increase in fibrinogen binding of ADP-activated
platelets that are treated by mFab7 versus treated by control Fab is significant as
determined by ANOVA.
4.5.5 Cytoskeletal Incorporation
In order to explore CD9 effects on the integrin-cytoskeleton linkage, core
cytoskeletons were prepared from mFab7 treated platelets. Platelet samples
were lysed at five min after addition of agonist. mFab7 increased the
incorporation of the cytoskeletal proteins actin binding protein (ABP), α-actinin,
and actin into the core cytoskeleton compared to control-treated platelets
(Fig 4.15A). Platelets activated by 2 μM ADP, pre-incubated with control Fab or
without Fab, did not form stable aggregates, and thus the incorporation of these
proteins was similar to the level of incorporation in resting platelets. Similarly,
incubation with mFab7 or control Fab in the absence of ADP did not increase
cytoskeletal protein incorporation. However, when platelets were incubated with
mFab7 and activated with 2 μM ADP, the incorporation of ABP, α-actinin, and
actin into the core cytoskeleton increased to levels higher than seen with mFab7
or ADP alone. The level of incorporation was similar to levels observed when
platelets were activated with 5 μM ADP, a concentration which allows formation
of more stable aggregates. The relative density of actin incorporated into the
platelet cytoskeletons is shown (Fig 4.15B). Statistical significance is designated
by asterisks.
4.5.6 Akt Phosphorylation
In order to examine possible signaling molecules involved in CD9mediated platelet functions, platelets were pretreated with mFab7, control Fab, or
saline control and stirred in the aggregometer, with or without threshold ADP, for
5 minutes. Total platelet lysates were separated and transferred to a PVDF
membrane, which was blotted with the antibody 4G10. This antibody is capable
of binding to phosphorylated tyrosine residues without preference for a particular
protein. This resulted in the appearance of several bands, most prominently Akt.
However, CD9 ligation by mFab7 did not appear to alter the intensity of any of
the bands (4G10 data not shown).
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Figure 4.14 CD9 Affects Ligand Binding
Platelet incubation with mFab7 results in increased fibrinogen binding in the
presence of ADP as indicated by increased PAC-1 binding. mFab7 does not
affect fibrinogen binding in resting platelets. **, p<0.01. n=4.
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Figure 4.15 CD9 Alters the Platelet Core Cytoskeleton
A, Coomassie-blue-stained reduced gel showing increase in ABP, myosin, actinin, and actin in the presence of ADP and mFab7. Lanes: A, total platelet
lysates, at 50% platelet count compared to other lanes; B, resting platelets; C,
treated with 2 μM ADP; D, treated with mFab7; E, treated with control Fab; F,
treated with 2 μM ADP+mFab7; G, treated with 2uM ADP+control Fab; H, treated
with 5 μM ADP; I, molecular weight standards. B, Quantification of actin
incorporated into core cytoskeleton. *, p<0.05; **, p<0.01. n=3.
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Akt has been shown to be involved in CD9-related signaling cascades
(Kotha 2008, Saito 2006), and its phosphorylation has been shown to be reduced
by the tetraspanin CD151 in rat fibroblasts (Sawada 2003). For these reasons,
Akt phosphorylation was specifically studied. However, it did not appear that
mFab7 ligation to CD9 altered the level of phosphorylated Akt compared to
control Fab or saline treatments (Fig 4.16). Although it appears that Akt
phosphorylation is not involved in mediating the platelet activation through CD9
perturbation, it must be noted that the levels of Akt phosphosphorylation were
very weak even in the positive controls.
Examination of Akt phosphorylation in the absence of stirring or incubation
also showed that there was no effect induced by mFab7 ligation to CD9 (data not
shown).
Future work may determine specific conditions under which CD9
modulates the Akt pathway, or another signaling pathway in platelets may be
identified as crucial to the impact of CD9 on platelet phenotypes.
4.5.7 Tetraspanin Web Organization
Immunoprecipitations were carried out to observe the interactions
between GPIIb-IIIa, CD9, and CD63, key members of the tetraspanin web. This
web may be a critical scaffolding feature in the cell membrane, as well as having
key roles in regulating GPIIb-IIIa regulation.
GPIIb-IIIa was immunoprecipitated with the antibody 10E5, which is
capable of binding both active and inactive GPIIb-IIIa with equal affinity. It was
capable of immunoprecipitating equivalent levels of GPIIb-IIIa when platelets
were treated with mFab7 or control Fab, in the presence or absence of 2 μM
ADP. An equal level of CD9 was immunoprecipitated in all samples (Fig 4.17).
This indicates that although CD9 ligation via mFab7 may have a subtle impact on
CD9-GPIIb-IIIa interactions, it is not capable of abolishing this interaction. As
previous reports indicate that the CD9-GPIIb-IIIa interaction is not dependent on
platelet activation or integrin activation state, it is expected that mFab7 treatment
would be capable of encouraging activation without altering the tetraspaninintegrin association.
When platelets were treated with control Fab, CD63 was not coprecipitated with GPIIb-IIIa, even in the presence of 2 μM ADP. This
concentration of ADP is at the threshold of platelet activation and capable of
inducing a low level of CD63 surface expression among a portion of the platelets.
Interestingly, mFab7 treatment increased the amount of CD63 coprecipitated with GPIIb-IIIa. While this effect is most pronounced—as expected—
in conjunction with low-level ADP, CD63 is also co-precipitated in the absence of
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Figure 4.16 CD9 Perturbation Does Not Appear to Alter the
Phosphorylation of Akt
Western blot showing level of phosphorylated Akt from platelet lysates.
Treatments: mFab7+ADP; mFab7 without agonist; control Fab+ADP; control Fab
without agonist; Saline control+ADP; saline control without agonist. While it
appears that platelet activation via ADP increases Akt phosphorylation compared
to resting samples, there is not an appreciable difference in Akt phosphorylation
in samples treated with mFab7 versus controls. Similar results were seen in nonstirred platelets. n=2
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Figure 4.17 CD9 Perturbation Alters Tetraspanin Web Associations
A, GPIIb-IIIa immunoprecipitated by 10E5. B, CD63 co-immunoprecipitates with
GPIIb-IIIa in the presence of mFab7, even in the absence of agonist stimulation,
but does not co-immunoprecipitate with GPIIb-IIIa in the absence of mFab7, even
in when activated by weak agonist (2 μM ADP). C, CD9 co-immunoprecipitates
with GPIIb-IIIa equally, regardless of presence of mFab7 or ADP.
Lanes: 1,2: mFab7; 3,4: mFab7 + 2 μM ADP; 5,6: control Fab; 7,8: control Fab +
2 μM ADP.
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agonist. It is possible that a subset of platelets are mildly activated and thus
expressing CD63 on the surface. It is also possible that, post-lysis, Fab7 enables
association between CD63 from lysosomal membranes and GPIIb-IIIa/CD9 from
the cell surface or alpha granules. Future research on the importance of CD9 in
organization of the platelet tetraspanin web will likely yield exciting results.
4.5.8 Clot Retraction
Surprisingly, although CD9 perturbation was shown to modulate a wide
variety of platelet functions, treatment with mFab7 did not alter clot retraction of
platelets in PRP (Fig 4.18). Samples treated with mFab7, control Fab, saline, and
D3 had formed a clot by 5 minutes. Between 15 minutes and extending through
to overnight incubation when retraction was complete, the samples treated with
mFab7, control Fab, and saline exhibited a similar extent of platelet-mediated clot
retraction and at a similar rate. This was true whether platelets were at
250,000/mm3 or at 100,000/mm3. However, D3 samples were consistently
resistant to clot retraction.
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Figure 4.18 mFab7 Interaction with CD9 Does Not Alter Clot Retraction
Left to right, samples are: saline; 40 μg/ml control Fab; 40 μg/ml mFab7; 80
μg/ml D3. A, 5 minutes after addition of CaCl2, clots are formed in all samples.
B-F: Samples at 15 min, 30 min, 60 min, 120 min, and overnight. Samples
treated with D3 resist clot retraction. There is no observable difference in clot
retraction between samples treated with saline, control Fab, or mFab7. n=4.
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CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS
5.1 Conclusions
Tetraspanins have been implicated in a wide range of cell functions.
These include cell motility (Huang 2006), tumor cell metastasis (Takeda 2007),
cell proliferation (Ko 2006), differentiation (Unternaehrer 2007, Saito 2006),
sperm-egg fusion (Ziyyat 2006), and virus-induced syncytia formation (GordonElonso 2006).
5.1.1 Localization and Protein Partners of CD9
The content of the tetraspanin web was studied under conditions of resting
and activated platelets. As shown in Fig 4.1, the surface expression of CD9 was
found to be quite high on platelets, and was not found to be altered when
platelets were resting or activated with ADP or TRAP. However, there was a wide
variability in CD9 surface expression, which could contribute to the lack of
statistical significance. These observations suggest a role for CD9 in maintaining
the scaffolding of the tetraspanin web or modulating the function of proteins, such
as GPIIb-IIIa, in the tetraspanin web, and thus modulating the activation state of
platelets, rather than having a role directly involving or requiring platelet
activation. GPIIb-IIIa and CD151 were also found on the surface of resting
platelets, although the surface expression of these proteins was increased upon
platelet activation. The increase in expression is likely due to the fusion of
granules with the surface membrane upon activation. CD63 is not expressed on
the surface of resting platelets. It is mildly expressed under weak activation by
ADP, and surface expression is further increased under stronger activation by
TRAP, when platelet lysosomal membranes fuse with the platelet surface
membrane. GPIb is found on the surface of platelets, and surface expression
increases under ADP activation, but the surface expression is not increased
following activation by TRAP. This may be due to the receptor becoming shed or
endocytosed following potent activation (Bergmeier 2004).
Immunoprecipitations confirmed that CD9 and GPIIb-IIIa associate with
each other, as each was able to co-precipitate a portion of the other (Fig 4.2).
Eptifibatide, a small molecule which which mimics RGD-containing proteins and
binds to GPIIb-IIIa, did not alter the level of co-precipitation, indicating that ligand
binding does not alter the association between the integrin GPIIb-IIIa and the
tetraspanin CD9. This further suggests a role for CD9 in regulating GPIIb-IIIa in
both a resting and activated state.
The co-localization of CD9 and GPIIb-IIIa was also studied in spread
platelets. A portion of the two proteins were found to be co-localized (Fig 4.3),
consistent with immunoprecipitation data. Co-localization was observed at the
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platelet periphery and platelet-platelet contacts, suggesting that modulation of
GPIIb-IIIa by CD9 is most critical in forming or maintaining platelet-platelet
interactions and in platelet spreading (Fig 4.6). Both molecules were frequently
localized to platelet centers, as expected, since both have been reported as
members of alpha granules (Brisson 1997).
Platelets from patients with Glanzmann Thrombasthenia, who express a
disfunctional GPIIb-IIIa, were studied to analyze if integrin function is crucial to
association with CD9. These platelets were still able to adhere and spread on
fibrin and on fibrin-fibronectin, possibly through a contribution of CD9 or on other
platelet integrins. These platelets exhibited greater spreading on fibrin, and
decreased spreading on fibrin-fibronectin compared to normal controls (Fig 4.4).
It is possible that these platelets exhibit an altered spreading ability, or that the
alteration in spreading is due to an alteration in cytoskeletal linkages due to a
mutant GPIIb-IIIa. The spreading alterations could also be due to the activation of
different signaling cascades than normal due to activation of alternative integrins.
Co-localization of CD9 and GPIIb-IIIa did not appear to be impacted by mutation
of the integrin. It is interesting to note that flow cytometry confirmed a 10%
increase in CD9 expression (data not shown), suggesting that CD9 may be partly
compensating for the defective GPIIb-IIIa. However, it is possible that the
increased signal could be due to better access for antibody binding to CD9.
CD9 was found to localize to filopodia, lamellipodia, and platelet-platelet
contacts in spread platelets, leading to the hypothesis that CD9 was involved in
platelet spreading and platelet interactions, including thrombus stability (Fig 4.6
and Fig 4.7). Interestingly, multiple studies indicate CD9 clusters at cell-cell
contacts in a variety of cell types (Gordon-Elonso 2006, Nakamura 1995, Yang
2006).
It is interesting that CD9 was not found to localize to platelet-matrix
contact sites on any of the matrices studied (Fig 4.5). This indicates that CD9
may not have a direct involvement in platelet adhesion or in modulating GPIIbIIIa during matrix adhesion, but rather modulates GPIIb-IIIa activation during
platelet-platelet interactions. These findings are consistent with other published
reports, showing that tetraspanins do not localize to focal adhesions
(Berditchevski 1999) and that modulation of integrins by tetraspanins can
regulate adhesion strengthening but does not lead to cell adhesion to the
extracellular matrix itself (Hemler 2001, Berditchevski 2001, Lammerding 2003).
5.1.2 Platelet Functions Affected by CD9 Perturbation
Platelet spreading has been shown to be affected by tetraspanins. CD151
knock-out platelets exhibit impaired cell spreading on fibrinogen (Lau 2004), as
do platelets treated with CD63-blocking antibodies (Israels 2005). Additionally,
transfection of CD9 into Chinese Hamster Ovary (CHO cells) has been
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previously reported to increase CHO cell spreading on collagen and fibronectin
(Cook, 1999). We here show that CD9 is involved in platelet spreading on four
matrices: fibrin, cross-linked fibrin-fibronectin matrix, fibronectin, and fibrinogen
(Fig 4.9). These four matrices are all ligands for GPIIb-IIIa and are involved in
platelet functions. Fibronectin, an extracellular matrix protein, is exposed upon
vascular damage; fibrinogen is critical to platelet aggregation; fibrin is involved in
clot retraction; and fibrin-fibronectin is important to wound healing. On all these
matrices, spreading is enhanced by the presence of mFab7, an anti-CD9 Fab
fragment, although CD9 localization is not affected. Moreover, on fibrinfibronectin matrix, the presence of mFab7 increases the number of platelets
adherent to the coverslip.
Platelet aggregation has been shown to be impaired in studies using
CD151 knockout (Lau 2004) or TSSC-6 knockouts (Goschnick 2006). This,
combined with the results that CD9 localizes to platelet-platelet contacts, led to
the hypothesis that CD9 would be involved in thrombus stability. As shown in Fig
4.11, when platelets were activated by threshold levels of ADP or collagen,
preincubation with mFab7 increased thrombus formation and inhibited
spontaneous disaggregation. This effect was not seen with the potent agonist
TRAP, even at low levels. This could be due to the fact that TRAP seems to act
as an ―all-or-nothing‖ signal; i.e., at increasingly lower concentrations it still
induces a >70% aggregation, until the concentration is insufficient to elicit any
aggregatory response. However, in the absence of agonist, mFab7 cannot evoke
an aggregation response, even at concentrations as high as 100 μg/ml.
Interestingly, platelet aggregations employing recombinant CD9 EC2, tagged
with GST, show a decreased level of aggregation in response to low-dose ADP
compared with GST-VAMP (Kotha, unpublished data). Reports also indicate that
reduced CD9 surface expression correlate with increased platelet aggregation,
although no causal relationship has been established yet (Vrelust 2007). It is
possible that mFab7 treatment is inhibiting the ability of CD9 to restrain GPIIb-IIIa
to its inactive conformation.
Eptifibatide, a cyclic RGD heptapeptide which acts as a GPIIb-IIIa
antagonist, was used to examine platelet disaggregation responses. At threshold
levels of ADP, collagen, and TRAP, platelet aggregates were more stable over
fifteen minutes when they were pretreated with mFab7 compared to a
nonspecific fab control (Fig 4.12). This leads us to believe that CD9 activation or
blockade, via mFab7 treatment, can help stabilize the active conformation of
GPIIb-IIIa, in the presence of agonist. This effect is seen at low levels of agonist,
whereas at higher levels, the activation of GPIIb-IIIa is so sturdy as to
overshadow the effect of CD9.
To examine the methods by which CD9 is activating GPIIb-IIIa, ligand
binding assays were performed (Fig 4.14). mFab7, in the absence of agonist, did
not have any effect, while in the presence of 2 M ADP, there is a significant
increase in fibrinogen binding. This shows that CD9 does encourage GPIIb-IIIa to
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adopt a ligand-binding-competent conformation in the presence of agonist. In Fig
4.13, flow cytometric analysis revealed that P-selectin and CD63, markers of
platelet activation, were increased by mFab7 pretreatment combined with ADP
activation but not in the absence of platelet activation, revealing that in addition to
modulating GPIIb-IIIa, CD9 perturbation also encourages platelet activation and
release of platelet granules.
It is interesting that despite being strongly involved in other platelet
functions, CD9 perturbation did not alter clot retraction of platelets in PRP (Fig
4.18). It is possible that the fibrin binding to GPIIb-IIIa initiating clot retraction
leads to such a potent signal cascade, that any involvement of CD9 in clot
retraction is overshadowed. This is particularly pertinent, as the effects of CD9
modulation are particularly evident when platelets are mildly activated.
5.1.3 Mechanisms Involved in Contribution of CD9 to Platelet Function
As the platelet cytoskeleton plays a key role in platelet shape change,
including filopodial and lammellipodial formation and granule release, a critical
step in platelet spreading and aggregatory responses, any changes in
cytoskeletal proteins induced by mFab7 were assayed. It was found, in Fig 4.15,
that mFab7 treatment in the absence of aggregation did not impact incorporation
of key cytoskeletal proteins compared to nonspecific control Fab. While low-dose
(2 M) ADP induced aggregation, this aggregatory response was transient and
insufficient to cause increased incorporation of cytoskeletal proteins in the
absence of agonist stimulation. However, low-dose ADP combined with mFab7
treatment resulted in increased incorporation of cytoskeletal proteins, particularly
actin binding protein (ABP), -actinin, and actin. This increased incorporation
was statistically greater than either ADP treatment or mFab7 treatment alone,
and was similar to the more potent changes resulting from activation by 5 M
ADP.
Phosphorylation of signaling molecules were analyzed in an attempt to
clarify the signaling cascade in platelets pertinent to CD9. Total tyrosine
phosphorylation by the antibody 4G10 (not shown) indicated several proteins
altered by platelet activation, but did not elucidate any alterations induced by
CD9 ligation.
Akt phosphorylation in particular was examined (Fig 4.16), as Akt is
involved in CD9-related signaling cascades (Kotha 2008, Saito 2006), and 4G10
results indicated that Akt was particularly important in platelet activation.
However, CD9 binding did not alter the level of Akt phosphorylation in stirred or
non-stirred platelets. Furture work may elucidate specific conditions under which
CD9 modulates the Akt pathway. It is also possible that another signaling
pathway in platelets may be identified as crucial to the impact of CD9 on platelet
phenotypes. There are no known cytosolic binding partners for CD9 in human
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platelets, but as platelets have a putative PDZ binding domain on their cytosolic
tail, the possibility exists that an interaction will yet be defined.
The importance of CD9 to the interaction of the membrane proteins GPIIbIIIa, CD9, and CD63 in the tetraspanin web was also studied (Fig 4.17). CD9 and
GPIIb-IIIa association was consistent whether platelets were resting or activated,
and was not impacted by mFab7 binding to CD9. This does not rule out the
possibility that Fab treatment could be gently altering the association between
CD9 and GPIIb-IIIa, but it certainly shows that it neither prohibits nor encourages
the association. It is interesting that mFab7 treatment increased the association
of CD63 into the tetraspanin web. This could be an indirect effect, as mFab7
treatment increases platelet activation, and thus there is more CD63 on the
membrane to associate in the tetraspanin web. It is possible that events resulting
from mFab7 ligation to CD9 preferentially causes an increase in CD63 inclusion
into the tetraspanin web, and that CD9 modulates GPIIb-IIIa via CD63. It is worth
noting that CD9 perturbation increased CD63 association with GPIIb-IIIa even in
the absence of agonist, and thus it is possible that mFab7 treatment causes an
increased association in trans post-lysis. The importance of CD9 in organization
of the platelet tetraspanin web is worthy of further research.
5.2 Proposed Model
In the absence of CD9 perturbation via mFab7 or platelet agonist, CD9
exists in the tetraspanin web in association with GPIIb-IIIa, which assumes a
bent, inactivated conformation (Fig 5.1A).
The addition of mFab7, which binds to CD9 EC2, may modulate the
association between CD9 and GPIIb-IIIa, but this impact on CD9-GPIIb-IIIa
association is not sufficient to cause integrin activation (Fig 5.1B). mFab7 does
not interact with the receptor FcγRII, nor does it induce signaling through this
receptor.
In the presence of agonist, the alteration in CD9-GPIIb-IIIa interaction is
sufficient to stabilize the extended, active conformation of GPIIb-IIIa (Fig 5.1C).
This applies even to low, threshold levels of agonist, which would cause only a
weak, transient activation of GPIIb-IIIa in the absence of CD9 perturbation via
mFab7. Although mFab7 treatment does not completely abolish CD9-GPIIb-IIIa
interactions, it is possible that the mFab7 reduces the association of CD9 EC2
with the extracellular domains of GPIIb-IIIa, causing a phenotype associated with
reduced CD9 expression (Vrelust 2007). It is anticipated that the impact of CD9
perturbation would be diminished with increasing levels of agonist, as GPIIb-IIIa
would become more strongly activated.
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Figure 5.1 Proposed Model of CD9 Function in Platelets
A, Resting platelet membrane. B, Binding of mFab7 does not activate GPIIb-IIIa.
C, ADP in conjunction of mFab7 strongly activates GPIIb-IIIa. Black arrow,
inside-out signaling from the ADP receptors P2Y1 or P2Y12 leading to activation
and ligand binding of GPIIb-IIIa. Black circle, ligand bound to active GPIIb-IIIa.
D, activation leads to increased linkage to the cytoskeleton and increased
thrombus stability.
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Figure 5.1 (continued)
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The increase in GPIIb-IIIa activation caused by agonist in conjunction with
CD9 alteration then leads to increased linkage of integrin to the cytoskeleton and
increased stability of platelet agonists (Fig 5.1D).
5.3 Recommendations for Future Study
Further characterization of the mFab7-CD9 interaction will need to be
carried out. It is unknown at this time whether mFab7 ligation is performing an
activating or blocking role. It is possible that mFab7 ligation is activating a signal
cascade, which when combined with low-dose agonist, serves to encourage the
active conformation of GPIIb-IIIa. It is also possible that mFab7 is shifting the
conformation of CD9, leading to a direct change in the CD9-GPIIbIIIa interaction,
whether through large extracellular loop or the fourth transmembrane domain. It
could also be altering the association of CD9 with other tetraspanins (such as
CD151 or CD63) or with a ligand (such as FN). It is even plausible that mFab7 is
affecting CD9 function in trans, altering a possible extracellular interaction
between CD9 and GPIIb-IIIa on nearby platelets. In light of other experiments
involving CD9 function in platelets—such as the finding that platelet incubation
with CD9 EC2 recombinant peptides inhibit platelet aggregation (J Kotha,
unpublished data), or that decreased expression of CD9 is correlated with
increased platelet aggregation in human patients (Vrelust 2007)—it is possible
that CD9 encourages GPIIb-IIIa to maintain an inactive conformation, in balance
with the tetraspanins CD151 and CD63 which seem to support activation.
Treatment with mFab7 would then be blocking CD9 inhibition on GPIIb-IIIa,
resulting in platelet activation in response to agonist, similarly to patients with
reduced CD9 expression. Further characterization will shed light on this issue.
Further research using the mFab7 here created can also yield additional
insight. It remains unclear what signaling cascades may be involved, and under
what circumstances they may be modulated. Further characterization of the
tetraspanin web, and the impact of CD9 modulation by mFab7, will also be
valuable. This will provide vital information for characterizing the role of CD9 in
modulating platelet function. More specific analysis of the exact sequence of CD9
involved in mFab7 binding, as well as an analysis of the impact on its association
with GPIIb-IIIa, will be insightful. Studies involving CD9 EC2 recombinant
peptides may be a useful tool in characterizing the extracellular association
between CD9 and GPIIb-IIIa, although the possibility that mFab7 treatment could
also alter the transmembrane associations between CD9 and GPIIb-IIIa cannot
be ruled out at this point.
The CD9 knock-out mouse will also provide additional insight. At present,
it is unknown what effect disruption of CD9 expression has on the expression
levels of other tetraspanins and integrins on the platelet surface. Increased
availability of antibodies against these murine proteins will allow expression
levels to be quantified. Additionally, while the most obvious phenotype of these
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mice is reduced fertility in the females (LaNaour 2000), careful studies of platelet
function may reveal differences—which may involve increased aggregation and
activation, rather than the inhibition seen with other tetraspanin knock-out mice. It
is most likely that any change in platelet function will be seen using low
concentrations of agonists.
I propose that CD9 is involved in modulating the activation state of GPIIbIIIa. The addition of mFab7 to platelets, in the presence of ADP, reduces the CD9
EC2 interaction with GPIIb-IIIa, allowing GPIIb-IIIa to retain an active, extended
conformation rather than a bent, inactive conformation. It will be interesting to
see if patients expressing reduced levels of CD9 are more at risk for thrombotic
events; therapies targeting increased surface expression of CD9 may become
clinically relevant in the future.
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